BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92. [PMID: 10673190 DOI: 10.1164/ajrccm.161.2.9906015] [Cited by in Crossref: 733] [Cited by in F6Publishing: 598] [Article Influence: 33.3] [Reference Citation Analysis]
Number Citing Articles
1 Benza RL, Gomberg-maitland M, Naeije R, Arneson CP, Lang IM. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. The Journal of Heart and Lung Transplantation 2011;30:982-9. [DOI: 10.1016/j.healun.2011.03.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
2 Supomo S, Darmawan H, Arjana AZ. Role of pulmonary hemodynamics in determining 6-minute walk test result in atrial septal defect: an observational study. J Cardiothorac Surg 2018;13:51. [PMID: 29788983 DOI: 10.1186/s13019-018-0725-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Olschewski H, Hoeper MM, Borst MM, Ewert R, Grünig E, Kleber F, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-neick I, Wilkens H, Winkler J, Worth H. Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol 2007;96:301-30. [DOI: 10.1007/s00392-007-0508-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
4 Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1058-L1067. [PMID: 11597896 DOI: 10.1161/circulationaha.107.742510] [Cited by in Crossref: 686] [Cited by in F6Publishing: 247] [Article Influence: 32.7] [Reference Citation Analysis]
5 Jehn M, Gebhardt A, Liebers U, Kiran B, Scherer D, Endlicher W, Witt C. Heat Stress is Associated with Reduced Health Status in Pulmonary Arterial Hypertension: A Prospective Study Cohort. Lung 2014;192:619-24. [DOI: 10.1007/s00408-014-9587-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Oudiz RJ, Barst RJ, Hansen JE, Sun X, Garofano R, Wu X, Wasserman K. Cardiopulmonary Exercise Testing and Six-Minute Walk Correlations in Pulmonary Arterial Hypertension. The American Journal of Cardiology 2006;97:123-6. [DOI: 10.1016/j.amjcard.2005.07.129] [Cited by in Crossref: 100] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
7 Kasymjanova G, Correa JA, Kreisman H, Dajczman E, Pepe C, Dobson S, Lajeunesse L, Sharma R, Small D. Prognostic Value of the Six-Minute Walk in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2009;4:602-7. [DOI: 10.1097/jto.0b013e31819e77e8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
8 Ju CR, Zhang JH, Chen M, Chen RC. Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease. Biomarkers 2017;22:246-52. [PMID: 27323660 DOI: 10.1080/1354750X.2016.1203999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007;29:2134-53. [PMID: 18042471 DOI: 10.1016/j.clinthera.2007.10.009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
10 Schioppo T, Artusi C, Ciavarella T, Ingegnoli F, Murgo A, Zeni S, Chighizola C, Meroni PL. N-TproBNP as biomarker in systemic sclerosis.Clin Rev Allergy Immunol. 2012;43:292-301. [PMID: 22669751 DOI: 10.1007/s12016-012-8312-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Lang IM, Bonderman D, Kneussl M, Marx M. Paediatric pulmonary vascular disease. Paediatr Respir Rev 2004;5:238-48. [PMID: 15276136 DOI: 10.1016/j.prrv.2004.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Reesink HJ, van der Plas MN, Verhey NE, van Steenwijk RP, Kloek JJ, Bresser P. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2007;133:510-6. [PMID: 17258590 DOI: 10.1016/j.jtcvs.2006.10.020] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
13 van Rooijen SJ, Molenaar CJL, Schep G, van Lieshout RHMA, Beijer S, Dubbers R, Rademakers N, Papen-Botterhuis NE, van Kempen S, Carli F, Roumen RMH, Slooter GD. Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in Colorectal Cancer. Am J Phys Med Rehabil 2019;98:888-96. [PMID: 31090551 DOI: 10.1097/PHM.0000000000001221] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 12.5] [Reference Citation Analysis]
14 Bhogal S, Mukherjee D, Banerjee S, Islam AM, Daggubati R, Paul TK. Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. Current Problems in Cardiology 2018;43:217-31. [DOI: 10.1016/j.cpcardiol.2017.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Peters EL, Bogaard HJ, Vonk Noordegraaf A, de Man FS. Neurohormonal modulation in pulmonary arterial hypertension. Eur Respir J 2021;58:2004633. [PMID: 33766951 DOI: 10.1183/13993003.04633-2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41. [DOI: 10.1007/s00392-007-0526-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
17 Smith G, Reyes JT, Russell JL, Humpl T. Safety of Maximal Cardiopulmonary Exercise Testing in Pediatric Patients With Pulmonary Hypertension. Chest 2009;135:1209-14. [DOI: 10.1378/chest.08-1658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
18 Lumens J, Delhaas T, Kirn B, Arts T. Three-wall segment (TriSeg) model describing mechanics and hemodynamics of ventricular interaction. Ann Biomed Eng 2009;37:2234-55. [PMID: 19718527 DOI: 10.1007/s10439-009-9774-2] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
19 Lordan JL, Corris PA. Pulmonary arterial hypertension and lung transplantation. Expert Rev Respir Med 2011;5:441-54. [PMID: 21702664 DOI: 10.1586/ers.11.21] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
20 Mok M, Tsang P, Lam Y, Lo Y, Wong W, Lau C. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Lupus 2007;16:279-85. [DOI: 10.1177/0961203307076509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
21 Kabitz H, Bremer H, Schwoerer A, Sonntag F, Walterspacher S, Walker DJ, Ehlken N, Staehler G, Windisch W, Grünig E. The Combination of Exercise and Respiratory Training Improves Respiratory Muscle Function in Pulmonary Hypertension. Lung 2014;192:321-8. [DOI: 10.1007/s00408-013-9542-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
22 Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opin Pharmacother 2008;9:65-81. [PMID: 18076339 DOI: 10.1517/14656566.9.1.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
23 Chakinala MM, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulm Circ 2013;3:507-22. [PMID: 24618537 DOI: 10.1086/674456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
24 Mandic S, Walker R, Stevens E, Nye ER, Body D, Barclay L, Williams MJA. Estimating exercise capacity from walking tests in elderly individuals with stable coronary artery disease. Disability and Rehabilitation 2013;35:1853-8. [DOI: 10.3109/09638288.2012.759629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
25 Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT, Weissmann N, Grimminger F, Seeger W, Ghofrani HA. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. The Journal of Heart and Lung Transplantation 2017;36:957-67. [DOI: 10.1016/j.healun.2017.02.016] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 22.4] [Reference Citation Analysis]
26 Tschopp O, Schmid C, Speich R, Seifert B, Russi EW, Boehler A. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest 2006;129:1002-8. [PMID: 16608950 DOI: 10.1378/chest.129.4.1002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
27 Sharma T, Lau EM, Choudhary P, Torzillo PJ, Munoz PA, Simmons LR, Naeije R, Celermajer DS. Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. Eur Respir J 2015;45:700-8. [DOI: 10.1183/09031936.00089914] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
28 Sajkov D, Petrovsky N, Palange P. Management of dyspnea in advanced pulmonary arterial hypertension. Curr Opin Support Palliat Care 2010;4:76-84. [PMID: 20407377 DOI: 10.1097/SPC.0b013e328338c1e0] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
29 Hachulla E, Bervar JF, Launay D, Lamblin N, Perez T, Mouthon L, De Groote P, Tillie-leblond I, Humbert M. Dyspnée à l’effort chez le patient atteint de sclérodermie systémique : du symptôme au diagnostic étiologique. La Presse Médicale 2009;38:911-26. [DOI: 10.1016/j.lpm.2008.08.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Ries M. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). J Inherit Metab Dis 2017;40:343-56. [PMID: 28314976 DOI: 10.1007/s10545-017-0032-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
31 Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015;34:362-8. [PMID: 25312386 DOI: 10.1016/j.healun.2014.08.020] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
32 Yu AD, Garrity ER. Recipient selection. Chest Surgery Clinics of North America 2003;13:405-28. [DOI: 10.1016/s1052-3359(03)00057-7] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
33 Johns CS, Kiely DG, Swift AJ. Novel imaging techniques in pulmonary hypertension. Curr Opin Cardiol 2018;33:587-93. [PMID: 30124495 DOI: 10.1097/HCO.0000000000000559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
34 Cantisani C, Mattozzi C, Giancristoforo S, D'epiro S, Richetta AG. Bosentan treatment of digital ulcers related to autoimmune disorders. Drug Dev Res 2011;72:750-5. [DOI: 10.1002/ddr.20483] [Reference Citation Analysis]
35 Long J, Russo MJ, Muller C, Vigneswaran WT. Surgical treatment of pulmonary hypertension: Lung transplantation. Pulm Circ 2011;1:327-33. [PMID: 22140622 DOI: 10.4103/2045-8932.87297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
36 Edriss H, Selvan K, Denega T, Rodrigues T, Test V, Nugent K. The Complexity of Characteristics, Diagnoses and Treatment of Older Patients With Pulmonary Hypertension. Am J Med Sci 2018;355:13-20. [PMID: 29289256 DOI: 10.1016/j.amjms.2017.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lewis GD. Pulmonary Vascular Response Patterns to Exercise: Is there a Role for Pulmonary Arterial Pressure Assessment during Exercise in the Post-Dana Point Era? Adv Pulm Hypertens 2010;9:92-100. [PMID: 34422153 DOI: 10.21693/1933-088X-9.2.92] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
38 McGlinchey N, Peacock AJ. Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt? Drug Discov Today 2014;19:1236-40. [PMID: 24814434 DOI: 10.1016/j.drudis.2014.04.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Ilgin D, Ozalevli S, Kilinc O, Sevinc C, Cimrin AH, Ucan ES. Gait speed as a functional capacity indicator in patients with chronic obstructive pulmonary disease. Ann Thorac Med 2011;6:141-6. [PMID: 21760846 DOI: 10.4103/1817-1737.82448] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
40 Reis A, Santos M, Vicente M, Furtado I, Cruz C, Melo A, Carvalho L, Gonçalves F, Sa-Couto P, Almeida L. Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study. Biomed Res Int 2018;2018:3924517. [PMID: 29750153 DOI: 10.1155/2018/3924517] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
41 Reuter SE, Massy-westropp N, Evans AM. Reliability and validity of indices of hand-grip strength and endurance: EVALUATION OF GRIP STRENGTH AND ENDURANCE. Australian Occupational Therapy Journal 2011;58:82-7. [DOI: 10.1111/j.1440-1630.2010.00888.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
42 Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126:420-427. [PMID: 15302727 DOI: 10.1378/chest.126.2.420] [Cited by in Crossref: 155] [Cited by in F6Publishing: 128] [Article Influence: 8.6] [Reference Citation Analysis]
43 Lattanzio M, Scelsi L, Golino M, Lattuada M, Raineri C, Turco A, Giuntini C, Ceriani F, Curti M, Bonelli A, Piacentino F, Venturini M, Ghiringhelli S, Morandi F, De Ponti R, Ghio S. Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown) 2021;22:929-36. [PMID: 34482325 DOI: 10.2459/JCM.0000000000001250] [Reference Citation Analysis]
44 Donini LM, Poggiogalle E, Mosca V, Pinto A, Brunani A, Capodaglio P. Disability affects the 6-minute walking distance in obese subjects (BMI>40 kg/m(2)). PLoS One 2013;8:e75491. [PMID: 24146756 DOI: 10.1371/journal.pone.0075491] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
45 Wardle AJ, Seager MJ, Wardle R, Tulloh RM, Gibbs JS. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database Syst Rev 2016;:CD011205. [PMID: 27482837 DOI: 10.1002/14651858.CD011205.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
46 Bauer R, Dehnert C, Schoene P, Filusch A, Bärtsch P, Borst MM, Katus HA, Joachim Meyer F. Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respiratory Medicine 2007;101:2366-9. [DOI: 10.1016/j.rmed.2007.06.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
47 Arena R, Sietsema KE. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. Circulation 2011;123:668-80. [PMID: 21321183 DOI: 10.1161/CIRCULATIONAHA.109.914788] [Cited by in Crossref: 120] [Cited by in F6Publishing: 46] [Article Influence: 10.9] [Reference Citation Analysis]
48 Díaz-Caraballo E, González-García AE, Reñones M, Sánchez-Recalde A, García-Río F, Oliver-Ruiz JM. Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome. Rev Esp Cardiol 2009;62:1046-9. [PMID: 19712626 DOI: 10.1016/s1885-5857(09)73271-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
49 Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE. The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulm Circ 2017;7:384-90. [PMID: 28597751 DOI: 10.1177/2045893217695568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006;100:1734-41. [PMID: 16545950 DOI: 10.1016/j.rmed.2006.02.004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
51 Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine 2022;196:106801. [DOI: 10.1016/j.rmed.2022.106801] [Reference Citation Analysis]
52 Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, Hill NS. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest 2006;130:1471-80. [PMID: 17099026 DOI: 10.1378/chest.130.5.1471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
53 Tanaka T, Morishita S, Hashimoto M, Nakamichi T, Uchiyama Y, Hasegawa S, Domen K. Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma. Support Care Cancer 2019;27:4107-13. [PMID: 30788627 DOI: 10.1007/s00520-019-04704-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Radchenko GD, Zhyvylo IO, Titov EY, Sirenko YM. Systemic Arterial Stiffness in New Diagnosed Idiopathic Pulmonary Arterial Hypertension Patients. Vasc Health Risk Manag 2020;16:29-39. [PMID: 32021226 DOI: 10.2147/VHRM.S230041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 O'Donnell DE, Elbehairy AF, Berton DC, Domnik NJ, Neder JA. Advances in the Evaluation of Respiratory Pathophysiology during Exercise in Chronic Lung Diseases. Front Physiol 2017;8:82. [PMID: 28275353 DOI: 10.3389/fphys.2017.00082] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
56 Russell S, Beghetti M, Oudiz R, Balagtas C, Zhang M, Ivy D. Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. Open Heart 2019;6:e001149. [PMID: 31908813 DOI: 10.1136/openhrt-2019-001149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Hronek M, Kovarik M, Aimova P, Koblizek V, Pavlikova L, Salajka F, Zadak Z. Skinfold Anthropometry –The Accurate Method for Fat Free Mass Measurement in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:597-603. [DOI: 10.3109/15412555.2013.781151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
58 Sun P, Jiang X, Gomberg-maitland M, Zhao Q, He J, Yuan P, Zhang R, Jing Z. Prolonged QRS Duration. Chest 2012;141:374-80. [DOI: 10.1378/chest.10-3331] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
59 Gomberg-maitland M, Huo D, Benza RL, Mclaughlin VV, Tapson VF, Barst RJ. Creation of a Model Comparing 6-Minute Walk Test to Metabolic Equivalent in Evaluating Treatment Effects in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 2007;26:732-8. [DOI: 10.1016/j.healun.2007.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
60 Suleman N, Frost AE. Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension. Chest 2004;126:808-15. [DOI: 10.1378/chest.126.3.808] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
61 Madden B. Pulmonary hypertension and pregnancy. International Journal of Obstetric Anesthesia 2009;18:156-64. [DOI: 10.1016/j.ijoa.2008.10.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
62 Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2:411-22. [PMID: 17323595 DOI: 10.2147/vhrm.2006.2.4.411] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
63 Schwaiblmair M, Faul C, von Scheidt W, Berghaus TM. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med 2012;12:23. [PMID: 22676304 DOI: 10.1186/1471-2466-12-23] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
64 Cabillic M, Rass-Roumeguere D, Peron T, Gouilly P, Beaumont M, Chambellan A. [A survey on the performance of the six-minute walk test]. Rev Mal Respir 2011;28:1111-23. [PMID: 22123137 DOI: 10.1016/j.rmr.2011.03.018] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Xiong CM, Lu XL, Shan GL, Wu BX, Zhu XY, Wu GH, Zeng XF, Guo T, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Tian HY, Li WM, Zhang DZ, Zhang C, Li MT, Liu HM, Guo YJ, Shen JY, Zhang WJ, Liu S, Zhou DX, Bao CD, Huang SA, Chen JY, Wu WF, Huang K, Li CL, Wang LH, He B, He JG, Li JJ. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. J Clin Pharmacol 2012;52:425-31. [PMID: 21415281 DOI: 10.1177/0091270011398241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
66 Kimura M, Kohno T, Kawakami T, Kataoka M, Tsugu T, Akita K, Isobe S, Itabashi Y, Maekawa Y, Murata M, Fukuda K. Midterm Effect of Balloon Pulmonary Angioplasty on Hemodynamics and Subclinical Myocardial Damage in Chronic Thromboembolic Pulmonary Hypertension. Can J Cardiol. 2017;33:463-470. [PMID: 28256427 DOI: 10.1016/j.cjca.2016.12.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
67 Moghetti P, Balducci S, Guidetti L, Mazzuca P, Rossi E, Schena F; Italian Society of Diabetology (SID),., Italian Association of Medical Diabetologists (AMD),., Italian Society of Motor and Sports Sciences (SISMES). Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Nutr Metab Cardiovasc Dis 2020;30:1882-98. [PMID: 32998820 DOI: 10.1016/j.numecd.2020.08.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
68 Mustafaoglu R, Demir R, Aslan GK, Sinan UY, Zeren M, Kucukoglu MS. Does Duke Activity Status Index help predicting functional exercise capacity and long-term prognosis in patients with pulmonary hypertension? Respir Med 2021;181:106375. [PMID: 33799051 DOI: 10.1016/j.rmed.2021.106375] [Reference Citation Analysis]
69 van Kessel M, Seaton D, Chan J, Yamada A, Kermeen F, Butler T, Sabapathy S, Morris N. Prognostic value of right ventricular free wall strain in pulmonary hypertension patients with pseudo-normalized tricuspid annular plane systolic excursion values. Int J Cardiovasc Imaging 2016;32:905-12. [DOI: 10.1007/s10554-016-0862-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
70 Costa GOS, Ramos RP, Oliveira RKF, Cepêda A, Vieira EB, Ivanaga IT, Ferreira EVM, Ota-Arakaki JS. Prognostic value of six-minute walk distance at a South American pulmonary hypertension referral center. Pulm Circ 2020;10:2045894019888422. [PMID: 32523683 DOI: 10.1177/2045894019888422] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Caffrey D, Miranda JJ, Gilman RH, Davila-Roman VG, Cabrera L, Dowling R, Stewart T, Bernabe-Ortiz A, Wise R, Leon-Velarde F, Checkley W; CRONICAS Cohort Study Group. A cross-sectional study of differences in 6-min walk distance in healthy adults residing at high altitude versus sea level. Extrem Physiol Med 2014;3:3. [PMID: 24484777 DOI: 10.1186/2046-7648-3-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD 2005;2:125-9. [PMID: 17136972 DOI: 10.1081/copd-200050527] [Cited by in Crossref: 154] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
73 Wilkins MR. Selective or Nonselective Endothelin Receptor Blockade in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2004;169:433-4. [DOI: 10.1164/rccm.2312017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
74 Friedberg F, Sohl SJ. Longitudinal change in chronic fatigue syndrome: what home-based assessments reveal. J Behav Med 2009;32:209-18. [PMID: 19101789 DOI: 10.1007/s10865-008-9189-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 Hoeper MM, Simon R. Gibbs J. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014;23:450-7. [DOI: 10.1183/09059180.00007814] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
76 Henkens IR, Gan CT, van Wolferen SA, Hew M, Boonstra A, Twisk JWR, Kamp O, van der Wall EE, Schalij MJ, Vonk Noordegraaf A, Vliegen HW. ECG monitoring of treatment response in pulmonary arterial hypertension patients. Chest 2008;134:1250-7. [PMID: 18641107 DOI: 10.1378/chest.08-0461] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
77 Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502. [PMID: 11985913 DOI: 10.1016/s0735-1097(02)01786-2] [Cited by in Crossref: 400] [Cited by in F6Publishing: 86] [Article Influence: 20.0] [Reference Citation Analysis]
78 Fukui S, Ogo T, Takaki H, Ueda J, Tsuji A, Morita Y, Kumasaka R, Arakawa T, Nakanishi M, Fukuda T, Yasuda S, Ogawa H, Nakanishi N, Goto Y. Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Heart 2016;102:1403-9. [PMID: 27220694 DOI: 10.1136/heartjnl-2015-309230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
79 Galiè N, Manes A, Branzi A. Prostanoids for Pulmonary Arterial Hypertension. Am J Respir Med 2003;2:123-37. [DOI: 10.1007/bf03256644] [Cited by in Crossref: 91] [Cited by in F6Publishing: 25] [Article Influence: 9.1] [Reference Citation Analysis]
80 Ernande L, Cottin V, Leroux PY, Girerd N, Huez S, Mulliez A, Bergerot C, Ovize M, Mornex JF, Cordier JF, Naeije R, Derumeaux G. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc Echocardiogr 2013;26:297-306. [PMID: 23265440 DOI: 10.1016/j.echo.2012.11.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
81 Argula RG, Strange C, Ramakrishnan V, Goldin J. Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. Chest. 2013;144:1578-1586. [PMID: 23828481 DOI: 10.1378/chest.12-2826] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
82 Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R, Keogh A, Oudiz R, Frost A, Blackburn S, Crow J, Rubin L. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2002;165:800-4. [DOI: 10.1164/ajrccm.165.6.2106079] [Cited by in Crossref: 920] [Cited by in F6Publishing: 729] [Article Influence: 46.0] [Reference Citation Analysis]
83 Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry B, Pulido T, Layton GR, Serdarevic-pehar M, Wessel DL. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension. Circulation 2012;125:324-34. [DOI: 10.1161/circulationaha.110.016667] [Cited by in Crossref: 229] [Cited by in F6Publishing: 102] [Article Influence: 22.9] [Reference Citation Analysis]
84 Iwasawa T, Fukui S, Kawakami M, Kawakami T, Kataoka M, Yuasa S, Fukuda K, Fujiwara T, Tsuji T. Factors related to instrumental activities of daily living in persons with chronic thromboembolic pulmonary hypertension. Chron Respir Dis 2021;18:14799731211046634. [PMID: 34592826 DOI: 10.1177/14799731211046634] [Reference Citation Analysis]
85 Deng X, Jin B, Li S, Li Y, Zhou H, Wu Y, Yan M, Hu Y, Qiu Q, Zhang G, Zheng X. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study. Clin Respir J 2019;13:693-9. [PMID: 31419027 DOI: 10.1111/crj.13076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Farkhooy A, Bellocchia M, Hedenström H, Libertucci D, Bucca C, Janson C, Solidoro P, Malinovschi A. Lung function in relation to six-minute walk test in pulmonary hypertension. Eur Clin Respir J 2020;7:1745492. [PMID: 32363016 DOI: 10.1080/20018525.2020.1745492] [Reference Citation Analysis]
87 Frachon I, Barnier A, Jobic Y, Gut-gobert C, Étienne Y, Crutu A, Mialon P, Pasquier E, Nowak E, Mejri M, Couturaud F, Leroyer C. Hypertension artérielle pulmonaire du sujet âgé. La cohorte d’un centre régional. Revue des Maladies Respiratoires 2010;27:30-6. [DOI: 10.1016/j.rmr.2009.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-172. [PMID: 20585012 DOI: 10.1161/circulationaha.109.898122] [Cited by in Crossref: 948] [Cited by in F6Publishing: 395] [Article Influence: 79.0] [Reference Citation Analysis]
89 Lee A, Button B, Ellis S, Stirling R, Wilson J, Holland A, Denehy L. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respiratory Medicine 2009;103:780-5. [DOI: 10.1016/j.rmed.2008.11.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
90 Bautmans I, Lambert M, Mets T. The six-minute walk test in community dwelling elderly: influence of health status. BMC Geriatr 2004;4:6. [PMID: 15272934 DOI: 10.1186/1471-2318-4-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 4.9] [Reference Citation Analysis]
91 Ehrmann Feldman D, Ducharme A, Frenette M, Giannetti N, Michel C, Grondin F, Sheppard R, Behlouli H, Pilote L. Factors related to time to admission to specialized multidisciplinary clinics in patients with congestive heart failure. Can J Cardiol 2009;25:e347-52. [PMID: 19812808 DOI: 10.1016/s0828-282x(09)70720-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Liu C, Liu K, Ji Z, Liu G. Treatments for pulmonary arterial hypertension. Respir Med 2006;100:765-74. [PMID: 16549344 DOI: 10.1016/j.rmed.2006.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
93 Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014;13:391-405. [PMID: 24261583 DOI: 10.1517/14740338.2014.859674] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
94 Seyfarth H, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy. Chest 2005;128:709-13. [DOI: 10.1378/chest.128.2.709] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
95 Minhas J, Shou H, Hershman S, Zamanian R, Ventetuolo CE, Bull T, Hemnes A, Chakinala MM, Mathai S, Al-Naamani N, Ellenberg S, Matura LA, Kawut SM, Shcherbina A. Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2021. [PMID: 34473938 DOI: 10.1513/AnnalsATS.202105-560OC] [Reference Citation Analysis]
96 Morris ZV, Chin LMK, Chan L, Guccione AA, Ahmad A, Keyser RE. Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance. Respir Med 2020;164:105900. [PMID: 32217288 DOI: 10.1016/j.rmed.2020.105900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Krishnan U, Horn EM. A Contemporary Approach to Pulmonary Arterial Hypertension. Curr Atheroscler Rep 2016;18:58. [PMID: 27491673 DOI: 10.1007/s11883-016-0608-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Torres Dde F, Zin WA, Lopes AJ, Vigário Pdos S, Garcia MI, Waetge D, Bandeira ML, Bessa LG, Guimarães FS. Association Between Hemodynamic Profile, Physical Capacity and Quality of Life in Pulmonary Hypertension. Arq Bras Cardiol 2015;104:387-93. [PMID: 25742419 DOI: 10.5935/abc.20150012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, Minson R, Hill C, Chow K, Sahhar J, Proudman S, Nikpour M. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012;14:R213. [PMID: 23039366 DOI: 10.1186/ar4051] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
100 Schneider M, Pistritto AM, Gerges C, Gerges M, Binder C, Lang I, Maurer G, Binder T, Goliasch G. Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. Int J Cardiovasc Imaging 2018;34:695-700. [PMID: 29230598 DOI: 10.1007/s10554-017-1279-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
101 Arena R, Lavie CJ, Milani RV, Myers J, Guazzi M. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: An evidence-based review. The Journal of Heart and Lung Transplantation 2010;29:159-73. [DOI: 10.1016/j.healun.2009.09.003] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 8.6] [Reference Citation Analysis]
102 Low A, Medford A, Millar A, Tulloh R. Lung function in pulmonary hypertension. Respiratory Medicine 2015;109:1244-9. [DOI: 10.1016/j.rmed.2015.05.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
103 Celli B. EPOC: desde el nihilismo no justificado a un optimismo razonable. Archivos de Bronconeumología 2002;38:585-8. [DOI: 10.1016/s0300-2896(02)75295-2] [Cited by in Crossref: 18] [Article Influence: 0.9] [Reference Citation Analysis]
104 Allcock RJ, O'Sullivan JJ, Corris PA. Atrial septostomy for pulmonary arterial hypertension. Heart 2003;89:1344-7. [PMID: 14594898 DOI: 10.1136/heart.89.11.1344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
105 Kuwana M, Watanabe H, Matsuoka N, Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open 2013;3:e003113. [PMID: 23906950 DOI: 10.1136/bmjopen-2013-003113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
106 Gong JN, Zhai ZG, Yang YH, Liu Y, Gu S, Kuang TG, Xie WM, Miao R, Wang C. Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Prospective Cohort Study. Chin Med J (Engl) 2015;128:3125-31. [PMID: 26612283 DOI: 10.4103/0366-6999.170267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
107 Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123:562-576. [PMID: 12576381 DOI: 10.1378/chest.123.2.562] [Cited by in Crossref: 112] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
108 Bishop BM, Mauro VF, Khouri SJ. Practical Considerations for the Pharmacotherapy of Pulmonary Arterial Hypertension. Pharmacotherapy 2012;32:838-55. [DOI: 10.1002/j.1875-9114.2012.01114.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
109 Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1269-75. [PMID: 20194810 DOI: 10.1164/rccm.200912-1856OC] [Cited by in Crossref: 135] [Cited by in F6Publishing: 58] [Article Influence: 11.3] [Reference Citation Analysis]
110 Porhownik NR, Myers R, Bshouty Z. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance. Can Respir J 2013;20:111-5. [PMID: 23616968 DOI: 10.1155/2013/474703] [Reference Citation Analysis]
111 Vermaete N, Wolter P, Verhoef G, Gosselink R. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol 2013;92:1007-21. [DOI: 10.1007/s00277-013-1689-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
112 Douwes JM, Roofthooft MT, Bartelds B, Talsma MD, Hillege HL, Berger RM. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. Int J Cardiol 2013;168:1370-7. [PMID: 23340486 DOI: 10.1016/j.ijcard.2012.12.080] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
113 Sadek Z, Ahmaidi S, Youness M, Awada C, Joumaa WH, Ramadan W. Combining aerobic interval, inspiratory and resistance trainings induces better cardiac remodelling and exercise capacity in heart failure patients. European Journal of Physiotherapy. [DOI: 10.1080/21679169.2021.2017477] [Reference Citation Analysis]
114 Gin P, Wang W, Yang S, Hsiao S, Tseng J. Right Heart Function in Systemic Lupus Erythematosus: Insights from Myocardial Doppler Tissue Imaging. Journal of the American Society of Echocardiography 2006;19:441-9. [DOI: 10.1016/j.echo.2005.10.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
115 Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. RheumatolInt. 2013;33:1047-1052. [PMID: 22833239 DOI: 10.1007/s00296-012-2466-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
116 Arena R. Exercise Testing and Training in Chronic Lung Disease and Pulmonary Arterial Hypertension. Progress in Cardiovascular Diseases 2011;53:454-63. [DOI: 10.1016/j.pcad.2011.02.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
117 McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431. [PMID: 17000921 DOI: 10.1161/circulationaha.104.503540] [Cited by in Crossref: 476] [Cited by in F6Publishing: 151] [Article Influence: 29.8] [Reference Citation Analysis]
118 Nagaya N, Shimizu Y, Satoh T, Oya H, Uematsu M, Kyotani S, Sakamaki F, Sato N, Nakanishi N, Miyatake K. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002;87:340-5. [PMID: 11907007 DOI: 10.1136/heart.87.4.340] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
119 Tian D, Huang H, Wen HY. Noninvasive methods for detection of chronic lung allograft dysfunction in lung transplantation. Transplant Rev (Orlando) 2020;34:100547. [PMID: 32498976 DOI: 10.1016/j.trre.2020.100547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Mccollister DH, Beutz M, Mclaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, Yaeger T, Weintraub P, Badesch DB. Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status. Psychosomatics 2010;51:339-339.e8. [DOI: 10.1016/s0033-3182(10)70706-4] [Cited by in Crossref: 48] [Article Influence: 4.0] [Reference Citation Analysis]
121 Lu XL, Xiong CM, Shan GL, Zhu XY, Wu BX, Wu GH, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Zhang DZ, Li WM, Zhang C, Tian HY, Guo YJ, Guo T, Liu HM, Zhang WJ, Gu H, Huang SA, Chen JY, Wu WF, Huang K, Li JJ, He JG. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther 2010;28:350-5. [PMID: 20637015 DOI: 10.1111/j.1755-5922.2010.00213.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
122 Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS One 2011;6:e27993. [PMID: 22110770 DOI: 10.1371/journal.pone.0027993] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
123 Chang CH, Lin HC, Yang CH, Gan ST, Huang CH, Chung FT, Hu HC, Lin SM, Chang CH. Factors Associated with Exercise-Induced Desaturation in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:2643-52. [PMID: 33122902 DOI: 10.2147/COPD.S272511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal 2006;27:589-95. [DOI: 10.1093/eurheartj/ehi728] [Cited by in Crossref: 182] [Cited by in F6Publishing: 150] [Article Influence: 11.4] [Reference Citation Analysis]
125 Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006;114:48-54. [DOI: 10.1161/circulationaha.106.630715] [Cited by in Crossref: 566] [Cited by in F6Publishing: 131] [Article Influence: 35.4] [Reference Citation Analysis]
126 Smit HJ, Vonk-noordegraaf A, Boonstra A, de Vries PM, Postmus PE. Assessment of the Pulmonary Volume Pulse in Idiopathic Pulmonary Arterial Hypertension by Means of Electrical Impedance Tomography. Respiration 2006;73:597-602. [DOI: 10.1159/000088694] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
127 Salzman SH. The 6-min walk test: clinical and research role, technique, coding, and reimbursement. Chest 2009;135:1345-52. [PMID: 19420202 DOI: 10.1378/chest.07-1682] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
128 Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med 2009;3:187-96. [PMID: 19885388 DOI: 10.1586/ERS.09.5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
129 Granton J. Outcomes in pulmonary hypertension: Beyond 40 metres. Canadian Journal of Cardiology 2010;26:12B-6B. [DOI: 10.1016/s0828-282x(10)71068-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Groepenhoff H, Vonk-noordegraaf A, Boonstra A, Spreeuwenberg MD, Postmus PE, Bogaard HJ. Exercise Testing to Estimate Survival in Pulmonary Hypertension. Medicine & Science in Sports & Exercise 2008;40:1725-32. [DOI: 10.1249/mss.0b013e31817c92c0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
131 Karanth MS, Awad NT. Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res 2017;11:OC34-8. [PMID: 28571188 DOI: 10.7860/JCDR/2017/24707.9723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
132 Helgeson SA, Imam JS, Moss JE, Hodge DO, Burger CD. Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. Diseases 2018;6:E33. [PMID: 29723983 DOI: 10.3390/diseases6020033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
133 Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007;28:75-89, viii. [PMID: 17338929 DOI: 10.1016/j.ccm.2006.11.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
134 Castleberry A, Mulvihill MS, Yerokun BA, Gulack BC, Englum B, Snyder L, Worni M, Osho A, Palmer S, Davis RD, Hartwig MG. The utility of 6-minute walk distance in predicting waitlist mortality for lung transplant candidates. J Heart Lung Transplant 2017;36:780-6. [PMID: 28131666 DOI: 10.1016/j.healun.2016.12.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
135 Tonelli AR, Alkukhun L, Arelli V, Ramos J, Newman J, McCarthy K, Pichurko B, Minai OA, Dweik RA. Value of impedance cardiography during 6-minute walk test in pulmonary hypertension. Clin Transl Sci 2013;6:474-80. [PMID: 24330692 DOI: 10.1111/cts.12090] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
136 Raposo-sonnenfeld I, Otero-gonzález I, Blanco-aparicio M, Ferrer-barba Á, Medrano-lópez C. Tratamiento con sildenafilo y/o bosentán en niños y jóvenes con hipertensión arterial pulmonar idiopática y síndrome de Eisenmenger. Revista Española de Cardiología 2007;60:366-72. [DOI: 10.1157/13101640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
137 Diller G, Gatzoulis MA. Pulmonary Vascular Disease in Adults With Congenital Heart Disease. Circulation 2007;115:1039-50. [DOI: 10.1161/circulationaha.105.592386] [Cited by in Crossref: 247] [Cited by in F6Publishing: 45] [Article Influence: 16.5] [Reference Citation Analysis]
138 Flox-Camacho A, Escribano-Subías P, Jiménez-López Guarch C, Fernández-Vaquero A, Martín-Ríos D, de la Calzada-Campo CS. Factors affecting the response to exercise in patients with severe pulmonary arterial hypertension. Arch Bronconeumol 2011;47:10-6. [PMID: 20889250 DOI: 10.1016/j.arbres.2010.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
139 Patel SS, Fernie JC, Taylor AL, Ivy DD, Rausch CM. Evaluation of predictive models for six minute walk test among children with pulmonary hypertension. Int J Cardiol 2017;227:393-8. [PMID: 27838122 DOI: 10.1016/j.ijcard.2016.11.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
140 Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, Winkler J, Seyfarth H, Gläser S, Blumberg F, Obst A, Dandel M, Hetzer R, Ewert R. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. International Journal of Cardiology 2013;167:1193-8. [DOI: 10.1016/j.ijcard.2012.03.135] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 7.6] [Reference Citation Analysis]
141 Montani D, Jaïs X, Ioos V, Sitbon O, Simonneau G, Humbert M. [Treatments for pulmonary arterial hypertension]. Rev Med Interne 2004;25:720-31. [PMID: 15471598 DOI: 10.1016/j.revmed.2004.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Saraff V, Schneider J, Colleselli V, Ruepp M, Rauchenzauner M, Neururer S, Geiger R, Högler W. Sex-, age-, and height-specific reference curves for the 6-min walk test in healthy children and adolescents. Eur J Pediatr 2015;174:837-40. [DOI: 10.1007/s00431-014-2454-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
143 Couillard A. Les facteurs pronostiques dans la BPCO : la tête, les jambes et le souffle ! Revue des Maladies Respiratoires 2011;28:174-86. [DOI: 10.1016/j.rmr.2010.09.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
144 Naeije R. The 6-Min Walk Distance in Pulmonary Arterial Hypertension. Chest 2010;137:1258-60. [DOI: 10.1378/chest.10-0351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
145 Bitker L, Sens F, Payet C, Turquier S, Duclos A, Cottin V, Juillard L. Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension. Am J Nephrol 2018;47:134-43. [DOI: 10.1159/000487198] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
146 Kreider M, Hadjiliadis D, Kotloff RM. Candidate Selection, Timing of Listing, and Choice of Procedure for Lung Transplantation. Clinics in Chest Medicine 2011;32:199-211. [DOI: 10.1016/j.ccm.2011.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
147 Sunbul M, Kepez A, Kivrak T, Eroglu E, Ozben B, Yildizeli B, Mutlu B. Right ventricular longitudinal deformation parameters and exercise capacity : prognosis of patients with chronic thromboembolic pulmonary hypertension. Herz 2014;39:470-5. [PMID: 23740084 DOI: 10.1007/s00059-013-3842-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
148 Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res 2018;27:979-85. [PMID: 29260444 DOI: 10.1007/s11136-017-1759-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
149 Salvi D, Poffley E, Orchard E, Tarassenko L. The Mobile-Based 6-Minute Walk Test: Usability Study and Algorithm Development and Validation. JMIR Mhealth Uhealth 2020;8:e13756. [PMID: 31899457 DOI: 10.2196/13756] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
150 Moriello C, Mayo NE, Feldman L, Carli F. Validating the six-minute walk test as a measure of recovery after elective colon resection surgery. Arch Phys Med Rehabil 2008;89:1083-9. [PMID: 18503803 DOI: 10.1016/j.apmr.2007.11.031] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
151 Meinel K, Koestenberger M, Sallmon H, Hansmann G, Pieles GE. Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. Diagnostics (Basel) 2020;11:E49. [PMID: 33396225 DOI: 10.3390/diagnostics11010049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Kline JA, Hernandez-nino J, Rose GA, Norton HJ, Camargo CA. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism*: . Critical Care Medicine 2006;34:2773-80. [DOI: 10.1097/01.ccm.0000241154.55444.63] [Cited by in Crossref: 69] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
153 van Loon RLE, Hoendermis ES, Duffels MG, Vonk-noordegraaf A, Mulder BJ, Hillege HL, Berger RM. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist? American Heart Journal 2007;154:776-82. [DOI: 10.1016/j.ahj.2007.06.003] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 5.4] [Reference Citation Analysis]
154 Kiani A, Eslaminejad A, Shafeipour M, Razavi F, Seyyedi SR, Sharif-Kashani B, Emami H, Bakhshayesh-Karam M, Abedini A. Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2019;36:185-94. [PMID: 32476953 DOI: 10.36141/svdld.v36i3.7663] [Reference Citation Analysis]
155 Zhao QH, Peng FH, Wei H, He J, Chen FD, Di RM, Jiang X, Jiang R, Chen YJ, Heresi GA, Jing ZC. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2012;110:433-9. [PMID: 22560769 DOI: 10.1016/j.amjcard.2012.03.042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
156 Waxman AB, Farber HW. Using Clinical Trial End Points to Risk Stratify Patients with Pulmonary Arterial Hypertension. Circulation. 2015;132:2152-2161. [PMID: 26621638 DOI: 10.1161/circulationaha.114.012328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
157 Gashouta MA, Humbert M, Hassoun PM. Update in systemic sclerosis-associated pulmonary arterial hypertension. La Presse Médicale 2014;43:e293-304. [DOI: 10.1016/j.lpm.2014.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
158 Ataya A, Patel S, Cope J, Alnuaimat H. Pulmonary arterial hypertension and associated conditions. Dis Mon 2016;62:379-402. [PMID: 27083316 DOI: 10.1016/j.disamonth.2016.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
159 Pober DM, Freedson PS, Kline GM, Mcinnis KJ, Rippe JM. Development and Validation of a One-Mile Treadmill Walk Test to Predict Peak Oxygen Uptake in Healthy Adults Ages 40 to 79 Years. Can J Appl Physiol 2002;27:575-88. [DOI: 10.1139/h02-033] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
160 McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573-1619. [PMID: 19389575 DOI: 10.1016/j.jacc.2009.01.004] [Cited by in Crossref: 1108] [Cited by in F6Publishing: 932] [Article Influence: 85.2] [Reference Citation Analysis]
161 Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine 2010;16:S1-9. [DOI: 10.1097/01.mcp.0000370205.22885.98] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
162 Mendes AA, Roncal CG, da Costa VL, Japyassu FA, Oliveira FR, Sepúlveda DL, da Silva CA, Albuquerque ES, de Melo RJ, Loureiro R, Muniz MT. [Pulmonary hypertension associated with acquired immunodeficiency syndrome: presentation of five cases and review of the literature]. Rev Soc Bras Med Trop 2009;42:452-7. [PMID: 19802485 DOI: 10.1590/s0037-86822009000400018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 . Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. Revista Española de Cardiología 2005;58:523-66. [DOI: 10.1157/13074846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
164 Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Respir Med 2016;117:254-63. [PMID: 27492539 DOI: 10.1016/j.rmed.2016.06.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
165 Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537. [PMID: 19713419 DOI: 10.1093/eurheartj/ehp297] [Cited by in Crossref: 2170] [Cited by in F6Publishing: 1807] [Article Influence: 166.9] [Reference Citation Analysis]
166 Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, Mclaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RAF, Frumkin LR. Sitaxsentan Therapy for Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2004;169:441-7. [DOI: 10.1164/rccm.200307-957oc] [Cited by in Crossref: 479] [Cited by in F6Publishing: 95] [Article Influence: 26.6] [Reference Citation Analysis]
167 Okumus G, Aslan GK, Arseven O, Ongen G, Issever H, Kiyan E. The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. Clin Respir J 2018;12:119-25. [PMID: 27149246 DOI: 10.1111/crj.12495] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
168 Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.Chest. 2005;128:2368-2374. [PMID: 16236896 DOI: 10.1378/chest.128.4.2368] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 5.3] [Reference Citation Analysis]
169 Spencer L, Zafiropoulos B, Denniss W, Fowler D, Alison J, Celermajer D. Is there a learning effect when the 6-minute walk test is repeated in people with suspected pulmonary hypertension? Chron Respir Dis 2018;15:339-46. [PMID: 29361830 DOI: 10.1177/1479972317752762] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
170 Umemoto S, Abe K, Hosokawa K, Horimoto K, Saku K, Sakamoto T, Tsutsui H. Increased Pulmonary Arterial Compliance after Balloon Pulmonary Angioplasty Predicts Exercise Tolerance Improvement in Inoperable CTEPH Patients with Lower Pulmonary Arterial Pressure. Heart Lung 2021;52:8-15. [PMID: 34801772 DOI: 10.1016/j.hrtlng.2021.11.003] [Reference Citation Analysis]
171 Grünig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension. Respiration 2011;81:394-401. [DOI: 10.1159/000322475] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 8.8] [Reference Citation Analysis]
172 Palevo G, Keteyian SJ, Kang M, Caputo JL. Resistance exercise training improves heart function and physical fitness in stable patients with heart failure. J Cardiopulm Rehabil Prev 2009;29:294-8. [PMID: 19561521 DOI: 10.1097/HCR.0b013e3181ac784b] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
173 Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. European Heart Journal 2006;27:1485-94. [DOI: 10.1093/eurheartj/ehi891] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 12.6] [Reference Citation Analysis]
174 Wardle AJ, Tulloh RM, Wardle AJ. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd011205] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Hill NS, Roberts K, Preston I. Pulmonary hypertension trials: how can we do better? Expert Rev Respir Med 2015;9:551-8. [PMID: 26290120 DOI: 10.1586/17476348.2015.1074040] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14. [PMID: 15308510 DOI: 10.1136/ard.2003.017673] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
177 Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X, Petersen F, Riemekasten G. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol 2017;36:381-90. [PMID: 28028682 DOI: 10.1007/s10067-016-3504-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
178 Jardim C, Fernandes CJ, Souza R. Goal-oriented treatment of pulmonary arterial hypertension. Curr Opin Pulm Med 2014;20:409-13. [PMID: 25022319 DOI: 10.1097/MCP.0000000000000086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Kheyfets VO, O'Dell W, Smith T, Reilly JJ, Finol EA. Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension. J Biomech Eng 2013;135:61011-15. [PMID: 23699723 DOI: 10.1115/1.4024141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
180 Camargo VMD, Martins BDCDS, Jardim C, Fernandes CJC, Hovnanian A, Souza R. Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar. J bras pneumol 2009;35:423-30. [DOI: 10.1590/s1806-37132009000500006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
181 Lammi MR, Saketkoo LA, Gordon JK, Lauto P, Fagan K, Steen VD; PHAROS Investigators. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort. Respirology 2017;22:1386-92. [PMID: 28500695 DOI: 10.1111/resp.13067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
182 Sánchez Román J, García Hernández F, Castillo Palma M, Ocaña Medina C. Diagnóstico y tratamiento de la hipertensión pulmonar. Revista Clínica Española 2008;208:142-55. [DOI: 10.1157/13115823] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
183 Agrawal MB, Awad NT. Correlation between Six Minute Walk Test and Spirometry in Chronic Pulmonary Disease. J Clin Diagn Res 2015;9:OC01-4. [PMID: 26435980 DOI: 10.7860/JCDR/2015/13181.6311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
184 Arena R, Guazzi M, Myers J, Grinnen D, Forman DE, Lavie CJ. Cardiopulmonary exercise testing in the assessment of pulmonary hypertension. Expert Rev Respir Med 2011;5:281-93. [PMID: 21510737 DOI: 10.1586/ers.11.4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
185 Higgs C, Skinner M, Hale L. Outcomes of a community-based lifestyle programme for adults with diabetes or pre-diabetes. J Prim Health Care 2016;8:130-9. [PMID: 27477555 DOI: 10.1071/HC15038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
186 Minai OA, Gudavalli R, Mummadi S, Liu X, Mccarthy K, Dweik RA. Heart Rate Recovery Predicts Clinical Worsening in Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2012;185:400-8. [DOI: 10.1164/rccm.201105-0848oc] [Cited by in Crossref: 56] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
187 Wang L, Zhou W, Liang Y, Yang Y, Garcia EV, Chen J, Fang W. Right ventricular dyssynchrony in pulmonary hypertension: Phase analysis using FDG-PET imaging. J Nucl Cardiol 2017;24:69-78. [DOI: 10.1007/s12350-015-0341-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
188 Shi Y, Zheng D, Zhang L, Yu Z, Yan H, Ni Z, Qian J, Fang W. Six-minute walk test predicts all-cause mortality and technique failure in ambulatory peritoneal dialysis patients. Nephrology (Carlton) 2017;22:118-24. [PMID: 26773829 DOI: 10.1111/nep.12726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
189 Mese T, Guven B, Yilmazer MM, Karadeniz C, Ozdemir R, Doksoz O. Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension. Congenit Heart Dis 2018;13:506-11. [PMID: 30019380 DOI: 10.1111/chd.12616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
190 Morris NR, Seale H, Harris J, Hall K, Lin ACW, Kermeen F. Gas exchange responses during 6-min walk test in patients with pulmonary arterial hypertension: Gas exchange during 6MWT in PAH. Respirology 2017;22:165-71. [DOI: 10.1111/resp.12868] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kasović M, Štefan L, Petrić V. Normative data for the 6-min walk test in 11-14 year-olds: a population-based study. BMC Pulm Med 2021;21:297. [PMID: 34548058 DOI: 10.1186/s12890-021-01666-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Merlo CA, Orens JB. Selection of candidates for lung transplantation. Current Opinion in Organ Transplantation 2007;12:479-84. [DOI: 10.1097/mot.0b013e3282efefe5] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
193 Amabile N, Heiss C, Real WM, Minasi P, Mcglothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating Endothelial Microparticle Levels Predict Hemodynamic Severity of Pulmonary Hypertension. Am J Respir Crit Care Med 2008;177:1268-75. [DOI: 10.1164/rccm.200710-1458oc] [Cited by in Crossref: 140] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
194 Rose-Jones LJ, Mclaughlin VV. Pulmonary hypertension: types and treatments. Curr Cardiol Rev 2015;11:73-9. [PMID: 24251459 DOI: 10.2174/1573403x09666131117164122] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
195 Sehgal S, Chowdhury A, Rabih F, Gadre A, Park MM, Li M, Wang X, Highland KB; STep-count using an Accelerometer for Monitoring PAH—STAMP Study group. Counting Steps: A New Way to Monitor Patients with Pulmonary Arterial Hypertension. Lung 2019;197:501-8. [PMID: 31144016 DOI: 10.1007/s00408-019-00239-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
196 Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, Spruit MA, Masefield S, Casaburi R, Clini EM, Crouch R, Garcia-aymerich J, Garvey C, Goldstein RS, Hill K, Morgan M, Nici L, Pitta F, Ries AL, Singh SJ, Troosters T, Wijkstra PJ, Yawn BP, Zuwallack RL. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med 2015;192:1373-86. [DOI: 10.1164/rccm.201510-1966st] [Cited by in Crossref: 302] [Cited by in F6Publishing: 132] [Article Influence: 43.1] [Reference Citation Analysis]
197 Grünig E, Tiede H, Enyimayew EO, Ehlken N, Seyfarth H, Bossone E, D’andrea A, Naeije R, Olschewski H, Ulrich S, Nagel C, Halank M, Fischer C. Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension. Circulation 2013;128:2005-15. [DOI: 10.1161/circulationaha.113.001573] [Cited by in Crossref: 143] [Cited by in F6Publishing: 44] [Article Influence: 15.9] [Reference Citation Analysis]
198 Aliyu ZY, Suleiman A, Attah E, Mamman AI, Babadoko A, Nouraie M, Mendelsohn L, Kato GJ, Gordeuk VR, Gladwin MT. NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. Br J Haematol 2010;150:102-7. [PMID: 20408845 DOI: 10.1111/j.1365-2141.2010.08195.x] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
199 Porteous MK, Rivera-Lebron BN, Kreider M, Lee J, Kawut SM. Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ 2016;6:30-6. [PMID: 27076905 DOI: 10.1086/685022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
200 Mazurek JA, Vaidya A, Mathai SC, Roberts JD, Forfia PR. Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension. Pulm Circ 2017;7:361-71. [PMID: 28597759 DOI: 10.1177/2045893217694175] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
201 Suntharalingam J, Goldsmith K, Toshner M, Doughty N, Sheares KK, Hughes R, Jenkins D, Pepke-zaba J. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respiratory Medicine 2007;101:2254-62. [DOI: 10.1016/j.rmed.2007.06.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
202 Aubert JD, Juillerat-Jeanneret L. Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. J Med Chem 2016;59:8168-88. [PMID: 27266371 DOI: 10.1021/acs.jmedchem.5b01781] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
203 Huez S, Brimioulle S, Naeije R, Vachiéry J. Feasibility of Routine Pulmonary Arterial Impedance Measurements in Pulmonary Hypertension. Chest 2004;125:2121-8. [DOI: 10.1378/chest.125.6.2121] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
204 da Costa Junior AA, Ota-arakaki JS, Ramos RP, Uellendahl M, Mancuso FJN, Gil MA, Fischer CH, Moises VA, de Camargo Carvalho AC, Campos O. Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance. Int J Cardiovasc Imaging 2017;33:39-46. [DOI: 10.1007/s10554-016-0966-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
205 Zuckerman WA, Rosenzweig EB. Pulmonary hypertension in children with sickle cell disease. Expert Review of Respiratory Medicine 2014;5:233-43. [DOI: 10.1586/ers.11.6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
206 Schuuring MJ, Boekholdt SM, Windhausen A, Bouma BJ, Groenink M, Keijzers M, De Winter RJ, Koolbergen DR, Blom NA, Mulder BJ. Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. Neth Heart J 2011;19:509-13. [PMID: 22086272 DOI: 10.1007/s12471-011-0218-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
207 Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H. Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension. Res Cardiovasc Med 2015;4:e26487. [PMID: 26436071 DOI: 10.5812/cardiovascmed.26487v2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
208 Kopeć G, Tyrka A, Miszalski-Jamka T, Mikołajczyk T, Waligóra M, Guzik T, Podolec P. Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist. Heart Lung Circ 2012;21:671-8. [PMID: 22819097 DOI: 10.1016/j.hlc.2012.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
209 Maggiore SM, Jonson B, Richard JC, Jaber S, Lemaire F, Brochard L. Alveolar derecruitment at decremental positive end-expiratory pressure levels in acute lung injury: comparison with the lower inflection point, oxygenation, and compliance. Am J Respir Crit Care Med 2001;164:795-801. [PMID: 11549535 DOI: 10.1164/ajrccm.164.5.2006071] [Cited by in Crossref: 146] [Cited by in F6Publishing: 114] [Article Influence: 7.3] [Reference Citation Analysis]
210 Choudhary SS, Choudhary S. Exercise testing in assessment and management of patients in clinical practice - present situation. Lung India 2008;25:111-7. [PMID: 20165662 DOI: 10.4103/0970-2113.59592] [Reference Citation Analysis]
211 Alkon J, Humpl T, Manlhiot C, Mccrindle BW, Reyes JT, Friedberg MK. Usefulness of the Right Ventricular Systolic to Diastolic Duration Ratio to Predict Functional Capacity and Survival in Children With Pulmonary Arterial Hypertension. The American Journal of Cardiology 2010;106:430-6. [DOI: 10.1016/j.amjcard.2010.03.048] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 6.8] [Reference Citation Analysis]
212 Galiè N, Torbicki A. Pulmonary arterial hypertension: new ideas and perspectives. Heart 2001;85:475-80. [PMID: 11250981 DOI: 10.1136/heart.85.4.475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
213 Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013;62:D22-33. [PMID: 24355638 DOI: 10.1016/j.jacc.2013.10.027] [Cited by in Crossref: 538] [Cited by in F6Publishing: 465] [Article Influence: 67.3] [Reference Citation Analysis]
214 Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:73S-80S. [PMID: 15194182 DOI: 10.1016/j.jacc.2004.02.039] [Cited by in Crossref: 138] [Cited by in F6Publishing: 102] [Article Influence: 7.7] [Reference Citation Analysis]
215 Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009;29:635-46. [PMID: 19715380 DOI: 10.2165/11317820-000000000-00000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
216 Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70. [PMID: 14998614 DOI: 10.1016/j.jacc.2003.09.051] [Cited by in Crossref: 193] [Cited by in F6Publishing: 160] [Article Influence: 10.7] [Reference Citation Analysis]
217 Cascino TM, Ashur C, Richardson CR, Jackson EA, McLaughlin VV. Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States. Pulm Circ 2020;10:2045894020974926. [PMID: 33343883 DOI: 10.1177/2045894020974926] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Fowler RM, Gain KR, Gabbay E. Exercise intolerance in pulmonary arterial hypertension. Pulm Med 2012;2012:359204. [PMID: 22737582 DOI: 10.1155/2012/359204] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
219 Demir R, Küçükoğlu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol 2015;15:249-54. [PMID: 25880178 DOI: 10.5152/akd.2015.5834] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
220 Sabbahi A, Severin R, Ozemek C, Phillips SA, Arena R. The role of cardiopulmonary exercise testing and training in patients with pulmonary hypertension: making the case for this assessment and intervention to be considered a standard of care. Expert Rev Respir Med 2020;14:317-27. [PMID: 31869256 DOI: 10.1080/17476348.2020.1708196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Hascoët S, Baruteau AE, Humbert M, Simonneau G, Jais X, Petit J, Laux D, Sitbon O, Lambert V, Capderou A. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. J Heart Lung Transplant 2017;36:386-98. [PMID: 27866929 DOI: 10.1016/j.healun.2016.10.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
222 Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004;34:442-53. [PMID: 15305243 DOI: 10.1016/j.semarthrit.2003.11.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
223 Nauser TD, Stites SW. Pulmonary hypertension: new perspectives. Congest Heart Fail 2003;9:155-62. [PMID: 12826774 DOI: 10.1111/j.1527-5299.2002.01050.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
224 Donti A, Formigari R, Ragni L, Manes A, Galiè N, Picchio FM. Pulmonary arterial hypertension in the pediatric age. J Cardiovasc Med (Hagerstown) 2007;8:72-7. [PMID: 17255821 DOI: 10.2459/01.JCM.0000247440.97569.fd] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
225 Weisman IM, Zeballos RJ. Clinical exercise testing. Clin Chest Med 2001;22:679-701, viii. [PMID: 11787659 DOI: 10.1016/s0272-5231(05)70060-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
226 Kula S, Canbeyli F, Atasayan V, Tunaoğlu FS, Oğuz AD. A retrospective study on children with pulmonary arterial hypertension: A single-center experience. Anatol J Cardiol 2018;20:41-7. [PMID: 29952362 DOI: 10.14744/AnatolJCardiol.2018.78370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
227 Channick R, Williamson TL. Diagnosis and treatment of pulmonary arterial hypertension. Cardiol Clin 2004;22:441-52, vii. [PMID: 15302363 DOI: 10.1016/j.ccl.2004.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
228 Baggen VJM, Driessen MMP, Post MC, van Dijk AP, Roos-Hesselink JW, van den Bosch AE, Takkenberg JJM, Sieswerda GT. Echocardiographic findings associated with mortality ortransplant in patients with pulmonary arterial hypertension:A systematic review and meta-analysis. Neth Heart J 2016;24:374-89. [PMID: 27189216 DOI: 10.1007/s12471-016-0845-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
229 Hsu HH, Chen JS, Chen RJ, Ko WJ, Kuo SW, Wu ET, Wu MH, Wang JK, Lee YC. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Respir Med 2007;101:1556-62. [PMID: 17223329 DOI: 10.1016/j.rmed.2006.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
230 Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD. STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Pediatric Pulmonary Arterial Hypertension. Circulation 2014;129:1914-23. [DOI: 10.1161/circulationaha.113.005698] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
231 Rajagopal S, Forsha DE, Risum N, Hornik CP, Poms AD, Fortin TA, Tapson VF, Velazquez EJ, Kisslo J, Samad Z. Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views. J Am Soc Echocardiogr. 2014;27:657-665.e3. [PMID: 24656881 DOI: 10.1016/j.echo.2014.02.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
232 Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2013;:CD004434. [PMID: 23450552 DOI: 10.1002/14651858.CD004434.pub5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
233 Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-zaba J, Morrell NW. Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation 2010;122:920-7. [DOI: 10.1161/circulationaha.109.933762] [Cited by in Crossref: 424] [Cited by in F6Publishing: 248] [Article Influence: 35.3] [Reference Citation Analysis]
234 Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P, Youssef P, Celermajer DS. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. Intern Med J 2013;43:32-7. [PMID: 22032309 DOI: 10.1111/j.1445-5994.2011.02624.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
235 Scholzel BE, Post MC, Thijs Plokker HW, Snijder RJ. Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension. Lung 2012;190:161-7. [PMID: 22160210 DOI: 10.1007/s00408-011-9350-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
236 Corris PA. Alternatives to Lung Transplantation: Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 2011;32:399-410. [DOI: 10.1016/j.ccm.2011.02.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
237 Tobita K, Goda A, Nishida Y, Takeuchi K, Kikuchi H, Inami T, Kohno T, Yamada S, Soejima K, Satoh T. Factors contributing to exercise capacity in chronic thromboembolic pulmonary hypertension with near-normal hemodynamics. J Heart Lung Transplant 2021;40:677-86. [PMID: 33879384 DOI: 10.1016/j.healun.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
238 Blyth KG, Syyed R, Chalmers J, Foster JE, Saba T, Naeije R, Melot C, Peacock AJ. Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. Respiratory Medicine 2007;101:2495-501. [DOI: 10.1016/j.rmed.2007.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
239 Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MCS, Wraith JE, Beck M, Arash L, Scarpa M, Yu Z, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. The Journal of Pediatrics 2006;148:533-539.e6. [DOI: 10.1016/j.jpeds.2005.12.014] [Cited by in Crossref: 265] [Cited by in F6Publishing: 227] [Article Influence: 16.6] [Reference Citation Analysis]
240 Sayegh ALC, Silva BM, Ferreira EVM, Ramos RP, Fisher JP, Nery LE, Ota-Arakaki JS, Oliveira RKF. Clinical utility of ventilatory and gas exchange evaluation during low-intensity exercise for risk stratification and prognostication in pulmonary arterial hypertension. Respirology 2021;26:264-72. [PMID: 33118293 DOI: 10.1111/resp.13959] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Morishita S, Kaida K, Ikegame K, Yoshihara S, Taniguchi K, Okada M, Kodama N, Ogawa H, Domen K. Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Support Care Cancer 2012;20:821-9. [DOI: 10.1007/s00520-011-1156-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
242 Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary Arterial Hypertension. Chest 2005;127:1836-43. [DOI: 10.1378/chest.127.5.1836] [Cited by in Crossref: 139] [Cited by in F6Publishing: 112] [Article Influence: 8.2] [Reference Citation Analysis]
243 Wang S, Pan J, Xiao B, Tang Y, Lan J, Zheng X, Yang C, Xu D, Zhang J. Immediate and short-term effects of transcatheter device closure of large atrial septal defect in senior people. Congenit Heart Dis 2019;14:939-44. [PMID: 31513356 DOI: 10.1111/chd.12844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
244 Ramakrishna G, Sprung J, Barugur BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery. J Am Coll Cardiol. 2005;45:1691-1699. [PMID: 15893189 DOI: 10.1016/j.jacc.2005.02.055] [Cited by in Crossref: 256] [Cited by in F6Publishing: 169] [Article Influence: 15.1] [Reference Citation Analysis]
245 de Torres JP, Pinto-plata V, Ingenito E, Bagley P, Gray A, Berger R, Celli B. Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest 2002;121:1092-8. [DOI: 10.1378/chest.121.4.1092] [Cited by in Crossref: 135] [Cited by in F6Publishing: 127] [Article Influence: 6.8] [Reference Citation Analysis]
246 Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52. [PMID: 16537877 DOI: 10.1378/chest.129.3.746] [Cited by in Crossref: 515] [Cited by in F6Publishing: 421] [Article Influence: 32.2] [Reference Citation Analysis]
247 Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J Heart Lung Transplant 2009;28:280-4. [PMID: 19285621 DOI: 10.1016/j.healun.2008.12.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
248 Pugh ME, Buchowski MS, Robbins IM, Newman JH, Hemnes AR. Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest 2012;142:1391-8. [PMID: 22576635 DOI: 10.1378/chest.12-0150] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
249 Schuuring MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag 2010;6:359-66. [PMID: 20856682 DOI: 10.2147/tcrm.s8397] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
250 Wang LY, Lee KT, Lin CP, Hsu LA, Wang CL, Hsu TS, Ho WJ. Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan. Acta Cardiol Sin 2017;33:498-509. [PMID: 28959103 DOI: 10.6515/acs20170612a] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
251 Bossone E, Paciocco G, Iarussi D, Agretto A, Iacono A, Gillespie BW, Rubenfire M. The Prognostic Role of the ECG in Primary Pulmonary Hypertension. Chest 2002;121:513-8. [DOI: 10.1378/chest.121.2.513] [Cited by in Crossref: 90] [Cited by in F6Publishing: 63] [Article Influence: 4.5] [Reference Citation Analysis]
252 Matsuda H, Ogino H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, Kobayashi J, Yagihara T, Kitamura S. Long-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. The Annals of Thoracic Surgery 2006;82:1338-43. [DOI: 10.1016/j.athoracsur.2006.03.105] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
253 Lammers AE, Burch M, Benden C, Elliott MJ, Rees P, Haworth SG, Aurora P. Lung transplantation in children with idiopathic pulmonary arterial hypertension: Transplantation in Pulmonary Hypertension. Pediatr Pulmonol 2010;45:263-9. [DOI: 10.1002/ppul.21168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
254 Ulrich S, Hildenbrand FF, Treder U, Fischler M, Keusch S, Speich R, Fasnacht M. Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm Med 2013;13:49. [PMID: 23915140 DOI: 10.1186/1471-2466-13-49] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
255 McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D73-D81. [PMID: 24355644 DOI: 10.1016/j.jacc.2013.10.034] [Cited by in Crossref: 209] [Cited by in F6Publishing: 168] [Article Influence: 26.1] [Reference Citation Analysis]
256 Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009;5:607-19. [PMID: 19688101 DOI: 10.2147/vhrm.s4713] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
257 Giusca S, Jurcut R, Coman IM, Ghiorghiu I, Catrina D, Popescu BA, Dima L, Ginghina C. Right Ventricular Function Predicts Clinical Response to Specific Vasodilator Therapy in Patients with Pulmonary Hypertension. Echocardiography 2013;30:17-26. [DOI: 10.1111/j.1540-8175.2012.01809.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
258 Bhogal S, Mukherjee D, Banerjee S, Tan W, Paul TK. Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. Curr Probl Cardiol 2018;43:191-216. [PMID: 29174585 DOI: 10.1016/j.cpcardiol.2017.10.002] [Reference Citation Analysis]
259 Sperandio EF, Arantes RL, Matheus AC, Silva RP, Lauria VT, Romiti M, Gagliardi AR, Dourado VZ. Intensity and physiological responses to the 6-minute walk test in middle-aged and older adults: a comparison with cardiopulmonary exercise testing. Braz J Med Biol Res 2015;48:349-53. [PMID: 25714888 DOI: 10.1590/1414-431X20144235] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
260 Darsaklis K, Dickson ME, Cornwell W 3rd, Ayers CR, Torres F, Chin KM, Matulevicius S. Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. Int J Cardiovasc Imaging 2016;32:1121-30. [PMID: 27076226 DOI: 10.1007/s10554-016-0883-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
261 Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010;104:1877-82. [PMID: 20547449 DOI: 10.1016/j.rmed.2010.05.009] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 7.8] [Reference Citation Analysis]
262 Sanchez O, Humbert M, Sitbon O, Jais X, Simonneau G. [Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir 2010;27:141-50. [PMID: 20206062 DOI: 10.1016/j.rmr.2009.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
263 Gupta S, Padhan P, Subhankar S, Singh P. Cardiovascular complications in patients with interstitial lung disease and their correlation with 6-minute walk test and spirometry: A single-center study. J Family Med Prim Care 2021;10:3330-5. [PMID: 34760753 DOI: 10.4103/jfmpc.jfmpc_350_21] [Reference Citation Analysis]
264 Farber HW. Validation of the 6-Minute Walk in Patients With Pulmonary Arterial Hypertension: Trying to Fit a Square Peg Into a Round Hole? Circulation 2012;126:258-60. [DOI: 10.1161/circulationaha.112.118547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
265 Bauml J, Haas A, Simone CB 2nd, Li SQ, Cohen RB, Langer CJ, Mao JJ. Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial. Integr Cancer Ther 2016;15:326-32. [PMID: 27114385 DOI: 10.1177/1534735415624138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
266 Keller RL, Moore P, Teitel D, Hawgood S, Mcquitty J, Fineman JR. Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy: . Pediatric Critical Care Medicine 2006;7:589-94. [DOI: 10.1097/01.pcc.0000244401.53189.cb] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
267 Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030. [PMID: 16456139 DOI: 10.1164/rccm.200510-1668oc] [Cited by in Crossref: 1161] [Cited by in F6Publishing: 389] [Article Influence: 72.6] [Reference Citation Analysis]
268 Lourenço AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol 2012;155:350-61. [PMID: 21641060 DOI: 10.1016/j.ijcard.2011.05.066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
269 LeVarge BL, Channick RN. The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints. Curr Opin Pulm Med 2015;21:438-45. [PMID: 26176969 DOI: 10.1097/MCP.0000000000000197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
270 Safdar Z, Thakur A, Singh S, Ji Y, Guffey D, Minard CG, Entman ML. Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. J Pulm Respir Med 2015;5:295. [PMID: 27170847 DOI: 10.4172/2161-105X.1000295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
271 Tissot C, Beghetti M. Advances in therapies for pediatric pulmonary arterial hypertension. Expert Rev Respir Med 2009;3:265-82. [PMID: 20477321 DOI: 10.1586/ers.09.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
272 Chatterjee S. Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum 2011;41:19-37. [PMID: 21047671 DOI: 10.1016/j.semarthrit.2010.08.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
273 Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-44. [PMID: 12737878 DOI: 10.1016/S0140-6736(03)13167-4] [Cited by in Crossref: 381] [Cited by in F6Publishing: 119] [Article Influence: 20.1] [Reference Citation Analysis]
274 Mansour A, Roushdy A, Harb B, Attia H. Noninvasive Predictors of Functional Capacity in Patients with Pulmonary Hypertension due to Congenital Heart Disease: A Pilot Echocardiography Single-Center Study. J Cardiovasc Echogr 2020;30:193-200. [PMID: 33828940 DOI: 10.4103/jcecho.jcecho_41_20] [Reference Citation Analysis]
275 Cristo Ropero MJ, Cruz-Utrilla A, Escribano-Subias MP. Epoprostenol for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2021;14:1005-13. [PMID: 34030557 DOI: 10.1080/17512433.2021.1929925] [Reference Citation Analysis]
276 Díaz-caraballo E, González-garcía AE, Reñones M, Sánchez-recalde Á, García-río F, Oliver-ruiz JM. Tratamiento a largo plazo con bosentán de cardiopatías congénitas complejas en situación de Eisenmenger. Revista Española de Cardiología 2009;62:1046-9. [DOI: 10.1016/s0300-8932(09)72103-7] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
277 Systrom D, Warren A, Naeije R. The Role of Exercise Testing in Pulmonary Vascular Disease: Diagnosis and Management. Clin Chest Med 2021;42:113-23. [PMID: 33541605 DOI: 10.1016/j.ccm.2020.11.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Marra A, Arcopinto M, Bossone E, Ehlken N, Cittadini A, Grünig E. Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives. Nutrition, Metabolism and Cardiovascular Diseases 2015;25:131-9. [DOI: 10.1016/j.numecd.2014.10.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
279 Gungor H, Fatih Ayik M, Engin C, Yagdi T, Atay Y, Ozbaran M, Nalbantgil S. Transthoracic echocardiographic and cardiopulmonary exercise testing parameters in Eisenmenger’s syndrome: Association with six-minute walk test distance. Herz 2014;39:633-7. [DOI: 10.1007/s00059-013-3880-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
280 Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy J, Simonneau G. Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2004;170:1212-7. [DOI: 10.1164/rccm.200404-445oc] [Cited by in Crossref: 151] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
281 Fowler RM, Jenkins SC, Maiorana AJ, Gain KR, O'driscoll G, Gabbay E. Measurement properties of the 6-min walk test in individuals with exercise-induced pulmonary arterial hypertension: 6-min walk in pulmonary hypertension. Internal Medicine Journal 2011;41:679-87. [DOI: 10.1111/j.1445-5994.2011.02501.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
282 Montes De Oca M, Ortega Balza M, Lezama J, López J. Enfermedad pulmonar obstructiva crónica. Evaluación de la tolerancia al ejercicio utilizando tres tipos diferentes de pruebas de esfuerzo. Archivos de Bronconeumología 2001;37:69-74. [DOI: 10.1016/s0300-2896(01)75017-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
283 Rovedder PME, Ziegler B, Pasin LR, Rampon G, Pinotti AFF, de Tarso Roth Dalcin P, Menna-barreto SS. Doppler echocardiogram, oxygen saturation and submaximum capacity of exercise in patients with cystic fibrosis. Journal of Cystic Fibrosis 2007;6:277-83. [DOI: 10.1016/j.jcf.2006.10.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
284 Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin LJ, Olschewski H. Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. Am J Respir Crit Care Med 2009;180:881-6. [DOI: 10.1164/rccm.200904-0563oc] [Cited by in Crossref: 104] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
285 Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, Boonstra A, Westerhof N, Bogaard HJ. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One 2013;8:e72013. [PMID: 24039732 DOI: 10.1371/journal.pone.0072013] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
286 von Siebenthal C, Aubert JD, Mitsakis P, Yerly P, Prior JO, Nicod LP. Pulmonary Hypertension and Indicators of Right Ventricular Function. Front Med (Lausanne) 2016;3:23. [PMID: 27376066 DOI: 10.3389/fmed.2016.00023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
287 Shlobin OA, Whitney Brown A, Weir N, Ahmad S, Lemma M, Nathan SD. Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations. Lung 2012;190:573-8. [DOI: 10.1007/s00408-012-9408-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
288 Cote CG, Pinto-plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD. Chest 2007;132:1778-85. [DOI: 10.1378/chest.07-2050] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 9.4] [Reference Citation Analysis]
289 Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationship. International Journal of Cardiology 2007;120:306-13. [DOI: 10.1016/j.ijcard.2006.10.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
290 Deljou A, Sabov M, Kane GC, Frantz RP, Dubrock HM, Martin DP, Schroeder DR, Johnson MQ, Weingarten TN, Sprung J. Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. Journal of Cardiothoracic and Vascular Anesthesia 2020;34:1506-13. [DOI: 10.1053/j.jvca.2019.10.059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
291 Mandras SA, Oleck S, Ventura HO. Pulmonary Arterial Hypertension and the Failing Ventricle: Getting It Right. Cardiovascular Innovations and Applications 2015;1:81-91. [DOI: 10.15212/cvia.2015.0010] [Reference Citation Analysis]
292 Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017;50:1700578. [DOI: 10.1183/13993003.00578-2017] [Cited by in Crossref: 119] [Cited by in F6Publishing: 86] [Article Influence: 23.8] [Reference Citation Analysis]
293 Jaijee S, Quinlan M, Tokarczuk P, Clemence M, Howard LSGE, Gibbs JSR, O'Regan DP. Exercise cardiac MRI unmasks right ventricular dysfunction in acute hypoxia and chronic pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2018;315:H950-7. [PMID: 29775415 DOI: 10.1152/ajpheart.00146.2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
294 Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, Bachmaier G, Olschewski A, Matucci-Cerinic M, Olschewski H. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS One 2016;11:e0168706. [PMID: 28030578 DOI: 10.1371/journal.pone.0168706] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
295 Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology., Council on Epidemiology and Prevention., Council on Peripheral Vascular Disease., Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010;122:191-225. [PMID: 20585013 DOI: 10.1161/CIR.0b013e3181e52e69] [Cited by in Crossref: 981] [Cited by in F6Publishing: 376] [Article Influence: 81.8] [Reference Citation Analysis]
296 Keogh A, Wlodarczyk J. Idiopathic- and scleroderma-related pulmonary arterial hypertension: outcomes and QOL on bosentan. Expert Rev Pharmacoecon Outcomes Res 2004;4:505-13. [PMID: 19807544 DOI: 10.1586/14737167.4.5.505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Overcash J. Assessing the Functional Status of Older Cancer Patients in an Ambulatory Care Visit. Healthcare (Basel) 2015;3:846-59. [PMID: 27417801 DOI: 10.3390/healthcare3030846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
298 Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, Gallop R, Christie J, Hansen-Flaschen J, Palevsky H. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005;6:92. [PMID: 16092961 DOI: 10.1186/1465-9921-6-92] [Cited by in Crossref: 103] [Cited by in F6Publishing: 110] [Article Influence: 6.1] [Reference Citation Analysis]
299 Ng SS, Yu PC, To FP, Chung JS, Cheung TH. Effect of walkway length and turning direction on the distance covered in the 6-minute walk test among adults over 50 years of age: a cross-sectional study. Physiotherapy 2013;99:63-70. [DOI: 10.1016/j.physio.2011.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
300 Dajczman E, Wardini R, Kasymjanova G, Préfontaine D, Baltzan MA, Wolkove N. Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation. Can Respir J 2015;22:225-9. [PMID: 26252533 DOI: 10.1155/2015/280187] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
301 Tomatsu S, Sawamoto K, Shimada T, Bober MB, Kubaski F, Yasuda E, Mason RW, Khan S, Alméciga-Díaz CJ, Barrera LA, Mackenzie WG, Orii T. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs 2015;3:1279-90. [PMID: 26973801 DOI: 10.1517/21678707.2015.1086640] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
302 Woods PR, Frantz RP, Taylor BJ, Olson TP, Johnson BD. The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:1133-42. [PMID: 21622009 DOI: 10.1016/j.healun.2011.03.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
303 Santos IF, Mendes AC. Hipertensão Pulmonar Primária Revisitada. Revista Portuguesa de Pneumologia 2000;6:383-94. [DOI: 10.1016/s0873-2159(15)30923-5] [Reference Citation Analysis]
304 Albert Barberà J. Hipertensión pulmonar: criterios actuales de diagnóstico y tratamiento. Medicina Clínica 2002;118:590-6. [DOI: 10.1016/s0025-7753(02)72461-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
305 Stevens GR, Sanz J. Diagnosis of pulmonary hypertension. Expert Opinion on Medical Diagnostics 2008;2:1263-77. [DOI: 10.1517/17530059.2.11.1263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
306 Bernard P, Romain AJ, Vancampfort D, Baillot A, Esseul E, Ninot G. Six minutes walk test for individuals with schizophrenia. Disability and Rehabilitation 2014;37:921-7. [DOI: 10.3109/09638288.2014.948136] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
307 Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Cathet Cardiovasc Intervent 2008;71:205-13. [DOI: 10.1002/ccd.21389] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
308 Ralph AP, Kenangalem E, Waramori G, Pontororing GJ, Sandjaja, Tjitra E, Maguire GP, Kelly PM, Anstey NM. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013;8:e80302. [PMID: 24312209 DOI: 10.1371/journal.pone.0080302] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
309 Nagaya N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N, Shirai M, Mori H, Miyatake K, Kangawa K. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004;109:351-6. [PMID: 14718403 DOI: 10.1161/01.CIR.0000109493.05849.14] [Cited by in Crossref: 80] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
310 Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA. Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization. Am J Cardiol 2012;109:1514-20. [PMID: 22360818 DOI: 10.1016/j.amjcard.2012.01.366] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
311 Naeije R, Huez S. Right ventricular function in pulmonary hypertension: physiological concepts. European Heart Journal Supplements 2007;9:H5-9. [DOI: 10.1093/eurheartj/sum023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
312 Skoro-sajer N, Lang I. The Role of Treprostinil in the Management of Pulmonary Hypertension: . American Journal of Cardiovascular Drugs 2008;8:213-7. [DOI: 10.2165/00129784-200808040-00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
313 Harbaum L, Hennigs JK, Baumann HJ, Lüneburg N, Griesch E, Bokemeyer C, Grünig E, Klose H. N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency. PLoS One 2014;9:e94263. [PMID: 24751887 DOI: 10.1371/journal.pone.0094263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
314 Roeseler J, Sottiaux T, Lemiale V, Lesny M, Beduneau G, Bialais E, Bradaï N, Castelain V, Dinomais M, Dousse N, Fontaine L, Guérin C, Hickmann C, Jougleux M, Kouki S, Leboucher F, Lemaire M, Nassaj A, Nunes J, Robain G, Thiollière F, Thivellier A, Wittebole X, Osman D, Bretonnière C, Boulain T, Chaoui K, Cravoisy A, Da Silva D, Djibré M, Fieux F, Hurel D, Lemiale V, Lesieur O, Lesny M, Milesi C, Misset B, Quenot J-, Soufir L, Vong L, Titomanlio L. Prise en charge de la mobilisation précoce en réanimation, chez l’adulte et l’enfant (électrostimulation incluse). Réanimation 2013;22:207-18. [DOI: 10.1007/s13546-013-0658-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 3.1] [Reference Citation Analysis]
315 Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respiratory Medicine 2005;99:1501-10. [DOI: 10.1016/j.rmed.2005.03.026] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
316 Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q 2007;30:20-43. [PMID: 17198034 DOI: 10.1097/00002727-200701000-00004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
317 Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic Peptides, Respiratory Disease, and the Right Heart. Chest 2004;126:1330-6. [DOI: 10.1378/chest.126.4.1330] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 5.4] [Reference Citation Analysis]
318 Lange TJ, Borst M, Ewert R, Halank M, Klose H, Leuchte H, Meyer FJ, Seyfarth HJ, Skowasch D, Wilkens H, Held M. [Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]. Pneumologie 2020;74:847-63. [PMID: 32663892 DOI: 10.1055/a-1199-1548] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
319 Pathak V, Aris R, Jensen BC, Huang W, Ford HJ. Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension. Lung 2018;196:315-9. [PMID: 29564533 DOI: 10.1007/s00408-018-0111-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
320 Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R. Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing. Circulation 2002;106:319-24. [DOI: 10.1161/01.cir.0000022687.18568.2a] [Cited by in Crossref: 375] [Cited by in F6Publishing: 95] [Article Influence: 18.8] [Reference Citation Analysis]
321 Degano B, Sitbon O, Savale L, Garcia G, O'callaghan DS, Jaïs X, Humbert M, Simonneau G. Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest 2010;137:1297-303. [DOI: 10.1378/chest.09-2060] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
322 Sharif Kashani B, Tahmaseb Pour P, Malekmohammad M, Behzadnia N, Sheybani-Afshar F, Fakhri M, Chaibakhsh S, Naghashzadeh F, Aidenlou S. Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: a clinical trial. J Cardiol 2014;64:231-5. [PMID: 24525046 DOI: 10.1016/j.jjcc.2014.01.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
323 Chaouat A, Canuet M, Kraemer J, Enache I, Ducoloné A, Kessler R, Weitzenblum E. Explorations fonctionnelles dans l’hypertension artérielle pulmonaire. Revue des Maladies Respiratoires 2005;22:991-7. [DOI: 10.1016/s0761-8425(05)85730-4] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
324 Faustini-pereira JL, Homercher-galant L, Garcia E, Brandão ABDM, Marroni CA. Exercise capacity of cirrhotic patients with hepatopulmonary syndrome. Annals of Hepatology 2015;14:361-8. [DOI: 10.1016/s1665-2681(19)31276-1] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
325 Akın A, Alehan D, Aykan HH, Özkutlu S, Özer S, Karagöz T. Serum Bcl-2 values in children with pulmonary hypertension. Pediatr Cardiol 2015;36:579-83. [PMID: 25381623 DOI: 10.1007/s00246-014-1052-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
326 Trow TK, McArdle JR. Diagnosis of pulmonary arterial hypertension. Clin Chest Med 2007;28:59-73, viii. [PMID: 17338928 DOI: 10.1016/j.ccm.2006.11.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
327 Wang L, Li W, Yang Y, Wu W, Cai Q, Ma X, Xiong C, He J, Fang W. Quantitative assessment of right ventricular glucose metabolism in idiopathic pulmonary arterial hypertension patients: a longitudinal study. Eur Heart J Cardiovasc Imaging 2016;17:1161-8. [DOI: 10.1093/ehjci/jev297] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
328 Park JH, Kusunose K, Kwon DH, Park MM, Erzurum SC, Thomas JD, Grimm RA, Griffin BP, Marwick TH, Popović ZB. Relationship between Right Ventricular Longitudinal Strain, Invasive Hemodynamics, and Functional Assessment in Pulmonary Arterial Hypertension. Korean Circ J 2015;45:398-407. [PMID: 26413108 DOI: 10.4070/kcj.2015.45.5.398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
329 Zotter-tufaro C, Mascherbauer J, Duca F, Koell B, Aschauer S, Kammerlander AA, Panzenboeck A, Sadushi-kolici R, Bangert C, Laimer D, Ristl R, Lang IM, Bonderman D. Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure 2015;3:459-66. [DOI: 10.1016/j.jchf.2015.01.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
330 Waxman AB. PULMONARY FUNCTION TEST ABNORMALITIES IN PULMONARY VASCULAR DISEASE AND CHRONIC HEART FAILURE. Clinics in Chest Medicine 2001;22:751-8. [DOI: 10.1016/s0272-5231(05)70063-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
331 Yoshida M, Adachi S, Imai R, Shimokata S, Nakano Y, Murohara T, Kondo T. <Editors' Choice> Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population. Nagoya J Med Sci 2021;83:321-30. [PMID: 34239180 DOI: 10.18999/nagjms.83.2.321] [Reference Citation Analysis]
332 Gupta V, Tonelli AR, Krasuski RA. Congenital heart disease and pulmonary hypertension. Heart Fail Clin 2012;8:427-45. [PMID: 22748904 DOI: 10.1016/j.hfc.2012.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
333 Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 2010;142:159-65. [PMID: 19176261 DOI: 10.1016/j.ijcard.2008.12.087] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
334 Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise. Chest 2002;121:1566-71. [DOI: 10.1378/chest.121.5.1566] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
335 Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci 2012;69:2805-31. [PMID: 22446747 DOI: 10.1007/s00018-012-0950-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
336 Chua R, Keogh AM, Byth K, O’loughlin A. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Internal Medicine Journal 2006;36:705-10. [DOI: 10.1111/j.1445-5994.2006.01169.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
337 Mccullagh B, Girgis RE. Exercise as an end-point in pulmonary hypertension trials: Pulmonary Hypertension Reviews: Perspective. International Journal of Clinical Practice 2010;64:4-6. [DOI: 10.1111/j.1742-1241.2009.02231.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
338 Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail 2015;8:1032-43. [PMID: 26185169 DOI: 10.1161/CIRCHEARTFAILURE.115.002130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 8.4] [Reference Citation Analysis]
339 Clark IN, Baker FA, Peiris CL, Shoebridge G, Taylor NF. The Brunel Music Rating Inventory-2 is a reliable and valid instrument for older cardiac rehabilitation patients selecting music for exercise. Psychology of Music 2016;44:249-62. [DOI: 10.1177/0305735614565830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001;25:335-40. [PMID: 11588011 DOI: 10.1165/ajrcmb.25.3.4424] [Cited by in Crossref: 327] [Cited by in F6Publishing: 324] [Article Influence: 15.6] [Reference Citation Analysis]
341 McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii25-iii31. [PMID: 19487219 DOI: 10.1093/rheumatology/kep107] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
342 Sato T, Tsujino I, Ohira H, Oyama-Manabe N, Ito YM, Yamada A, Ikeda D, Watanabe T, Nishimura M. Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. J Heart Lung Transplant 2015;34:414-23. [PMID: 25813768 DOI: 10.1016/j.healun.2015.01.984] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
343 Naeije R, Blanco I, Barberà JA. [The cardiopulmonary exercise test in the management of patients with pulmonary hypertension]. Arch Bronconeumol 2011;47 Suppl 7:15-20. [PMID: 23351471 DOI: 10.1016/S0300-2896(11)70055-2] [Reference Citation Analysis]
344 Corlateanu A, Plahotniuc A, Corlateanu O, Botnaru V, Bikov A, Mathioudakis AG, Covantev S, Siafakas N. Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respiratory Medicine 2021;185:106519. [DOI: 10.1016/j.rmed.2021.106519] [Reference Citation Analysis]
345 Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003;124:2087-92. [PMID: 14665484 DOI: 10.1378/chest.124.6.2087] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
346 Albanaqi AL, Rahimi GRM, Smart NA. Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biol Res Nurs 2021;23:442-54. [PMID: 33371736 DOI: 10.1177/1099800420982376] [Reference Citation Analysis]
347 Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123. [PMID: 11597664 DOI: 10.1016/s0140-6736(01)06250-x] [Cited by in Crossref: 1043] [Cited by in F6Publishing: 226] [Article Influence: 49.7] [Reference Citation Analysis]
348 Eliason G, Abdel-halim S, Arvidsson B, Kadi F, Piehl-aulin K. Physical performance and muscular characteristics in different stages of COPD. Scandinavian Journal of Medicine & Science in Sports 2009;19:865-70. [DOI: 10.1111/j.1600-0838.2008.00858.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
349 Huston JH, Brittain EL, Robbins IM. Pulmonary Hypertension and Right Ventricular Failure: Lung Transplant Versus Heart-Lung Transplant. Cardiol Clin 2020;38:269-81. [PMID: 32284103 DOI: 10.1016/j.ccl.2020.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
350 Tang C, Lee K, Ying K. Review of the diagnosis and pharmacological management of pulmonary arterial hypertension in connective tissue disease. Hong Kong Bulletin on Rheumatic Diseases 2016;16:14-22. [DOI: 10.1515/hkbrd-2016-0004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
351 Mcelhinney DB. A New START for Sildenafil in Pediatric Pulmonary Hypertension: Reframing the Dose–Survival Relationship in the STARTS-2 Trial. Circulation 2014;129:1905-8. [DOI: 10.1161/circulationaha.114.009584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
352 Ploegstra M, Zijlstra WM, Douwes JM, Hillege HL, Berger RM. Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. International Journal of Cardiology 2015;184:198-207. [DOI: 10.1016/j.ijcard.2015.01.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 9.1] [Reference Citation Analysis]
353 Kusunose K, Yamada H, Nishio S, Hirata Y, Seno H, Saijo Y, Ise T, Tobiume T, Yamaguchi K, Yagi S, Soeki T, Wakatsuki T, Sata M. Echocardiographic Predictors for Worsening of Six-Minute Walk Distances in Patients With Systemic Sclerosis (Scleroderma). The American Journal of Cardiology 2017;120:315-21. [DOI: 10.1016/j.amjcard.2017.04.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
354 Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism. Chest 2017;151:1058-68. [DOI: 10.1016/j.chest.2016.11.030] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 17.6] [Reference Citation Analysis]
355 . ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002;166:111-7. [DOI: 10.1164/ajrccm.166.1.at1102] [Cited by in Crossref: 5813] [Cited by in F6Publishing: 5485] [Article Influence: 290.7] [Reference Citation Analysis]
356 Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol 2011;57:1053-61. [PMID: 21349396 DOI: 10.1016/j.jacc.2010.11.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
357 Feldman DE, Ducharme A, Giannetti N, Frenette M, Michel C, Grondin F, Sheppard R, Lauriers JD, Behlouli H, Pilote L. Outcomes for Women and Men Who Attend a Heart Failure Clinic: Results of a 12-Month Longitudinal Study. Journal of Cardiac Failure 2011;17:540-6. [DOI: 10.1016/j.cardfail.2011.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
358 Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Jue K, Wolfe RS, Xie H, McHugo G, Santos M, Williams GE, Naslund JA, Mueser KT. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. Psychiatr Serv 2013;64:729-36. [PMID: 23677386 DOI: 10.1176/appi.ps.003622012] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
359 Keogh AM, Mcneil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Medical Journal of Australia 2003;178:564-7. [DOI: 10.5694/j.1326-5377.2003.tb05360.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
360 Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56. [PMID: 22696079 DOI: 10.1161/CIRCULATIONAHA.112.105890] [Cited by in Crossref: 152] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
361 Pi H, Kosanovich CM, Handen A, Tao M, Visina J, Vanspeybroeck G, Simon MA, Risbano MG, Desai A, Mathier MA, Rivera-Lebron BN, Nguyen Q, Kliner J, Nouraie M, Chan SY. Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center. Chest 2020;158:330-40. [PMID: 32109446 DOI: 10.1016/j.chest.2020.01.046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
362 Salles-Rojas A, Guzmán-Valderrábano C, Madrid WA, González-Molina A, Silva-Cerón M, Rodríguez-Hernández C, Salas-Escamilla I, Castorena-Maldonado A, López-García CA, Torre-Bouscoulet L, Gochicoa-Rangel L. Masking the 6-Minute Walking Test in the COVID-19 Era. Ann Am Thorac Soc 2021;18:1070-4. [PMID: 33315525 DOI: 10.1513/AnnalsATS.202009-1088RL] [Reference Citation Analysis]
363 Shah AC, Ma K, Faraoni D, Oh DCS, Rooke GA, Van Norman GA. Self-reported functional status predicts post-operative outcomes in non-cardiac surgery patients with pulmonary hypertension. PLoS One 2018;13:e0201914. [PMID: 30114222 DOI: 10.1371/journal.pone.0201914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
364 White AC, Terrin N, Miller KB, Ryan HF. Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation. Chest 2005;128:145-52. [DOI: 10.1378/chest.128.1.145] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
365 Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal 2006;151:851.e1-5. [DOI: 10.1016/j.ahj.2005.09.006] [Cited by in Crossref: 159] [Cited by in F6Publishing: 117] [Article Influence: 9.9] [Reference Citation Analysis]
366 Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for Pulmonary Arterial Hypertension. Am J Ther 2019;26:e520-6. [PMID: 30946047 DOI: 10.1097/MJT.0000000000000766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
367 Agarwal M, Waxman AB. Physiological Techniques and Pulmonary Hypertension - Left Heart Disease. Prog Cardiovasc Dis 2016;59:30-41. [PMID: 27211586 DOI: 10.1016/j.pcad.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
368 Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA, Connors G, Weir NA, Drinkard B, Lamberti J, Keyser RE. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013;143:333-43. [PMID: 22922554 DOI: 10.1378/chest.12-0993] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 13.3] [Reference Citation Analysis]
369 Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, Nordenholz KE, Diercks DB, Rondina MT, Klinger JR. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emerg Med Australas 2013;25:515-26. [PMID: 24224521 DOI: 10.1111/1742-6723.12159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
370 Barreto SS. Assessment of exercise capacity in pulmonary hypertension. J Bras Pneumol 2009;35:401-3. [PMID: 19547846 DOI: 10.1590/s1806-37132009000500002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
371 Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7. [PMID: 17502046 DOI: 10.1007/s11926-007-0010-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
372 Saggar R, Sitbon O. Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives. The American Journal of Cardiology 2012;110:S9-S15. [DOI: 10.1016/j.amjcard.2012.06.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
373 Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer M. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respiratory Medicine 2003;97:130-3. [DOI: 10.1053/rmed.2003.1440] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
374 Taichman DB, Mandel J. Epidemiology of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 2007;28:1-22. [DOI: 10.1016/j.ccm.2006.11.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
375 Sachdev A, Villarraga HR, Frantz RP, Mcgoon MD, Hsiao J, Maalouf JF, Ammash NM, Mccully RB, Miller FA, Pellikka PA, Oh JK, Kane GC. Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension. Chest 2011;139:1299-309. [DOI: 10.1378/chest.10-2015] [Cited by in Crossref: 220] [Cited by in F6Publishing: 197] [Article Influence: 20.0] [Reference Citation Analysis]
376 Stauber RE, Olschewski H. Portopulmonary hypertension: short review. Eur J Gastroenterol Hepatol. 2010;22:385-390. [PMID: 19907338 DOI: 10.1097/meg.0b013e3283337130] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
377 Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, Gall H. Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulm Circ 2020;10:2045894020961739. [PMID: 33088480 DOI: 10.1177/2045894020961739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
378 Brierre G, Blot-souletie N, Degano B, Tetu L, Bongard V, Carrie D. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. European Journal of Echocardiography 2010;11:516-22. [DOI: 10.1093/ejechocard/jeq011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
379 Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, Wensel R. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. European Journal of Heart Failure 2013;15:771-5. [DOI: 10.1093/eurjhf/hft044] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
380 Mehari A, Alam S, Tian X, Cuttica MJ, Barnett CF, Miles G, Xu D, Seamon C, Adams-Graves P, Castro OL, Minniti CP, Sachdev V, Taylor JG 6th, Kato GJ, Machado RF. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013;187:840-7. [PMID: 23348978 DOI: 10.1164/rccm.201207-1222OC] [Cited by in Crossref: 78] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
381 Rhodes CJ, Wharton J, Wilkins MR. Pulmonary Hypertension: Biomarkers. In: Humbert M, Evgenov OV, Stasch J, editors. Pharmacotherapy of Pulmonary Hypertension. Berlin: Springer Berlin Heidelberg; 2013. pp. 77-103. [DOI: 10.1007/978-3-662-45805-1_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
382 Montani D, Sitbon O, Jaïs X, Cabrol S, Simonneau G, Humbert M. Traitement de l’hypertension artérielle pulmonaire. La Presse Médicale 2005;34:1445-55. [DOI: 10.1016/s0755-4982(05)84206-x] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
383 Castleberry AW, Englum BR, Snyder LD, Worni M, Osho AA, Gulack BC, Palmer SM, Davis RD, Hartwig MG. The utility of preoperative six-minute-walk distance in lung transplantation. Am J Respir Crit Care Med. 2015;192:843-852. [PMID: 26067395 DOI: 10.1164/rccm.201409-1698oc] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
384 Karakurt Z, Güven AO, Moçin OY, Karavelioğlu Y, Güngör G, Altınöz H, Adıgüzel N, Yarkın T, Baran R. Six minute walking distance in kyphoscoliosis patients with chronic respiratory failure. Multidiscip Respir Med 2010;5:244-9. [PMID: 22958538 DOI: 10.1186/2049-6958-5-4-244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
385 Yagi K, Asakura T, Namkoong H, Suzuki S, Asami T, Okamori S, Kusumoto T, Funatsu Y, Kamata H, Nishimura T, Ishii M, Betsuyaku T, Hasegawa N. Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease. BMC Pulm Med 2018;18:114. [PMID: 30005658 DOI: 10.1186/s12890-018-0686-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
386 Mathai SC, Hassoun PM. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol 2009;21:642-8. [PMID: 19667994 DOI: 10.1097/BOR.0b013e3283307dc8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
387 Orgun LT, Öztürk Z, Canbeyli FH, Yapar D, Gücüyener K, Kula S. Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension. Pediatr Cardiol 2019;40:1494-502. [PMID: 31367954 DOI: 10.1007/s00246-019-02174-4] [Reference Citation Analysis]
388 van Hedel HJA, Wirz M, Dietz V. Standardized assessment of walking capacity after spinal cord injury: the European network approach. Neurological Research 2013;30:61-73. [DOI: 10.1179/016164107x230775] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 6.2] [Reference Citation Analysis]
389 Puente-maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, O'donnell DE, Onorati P, Porszasz J, Rabinovich R, Rossiter HB, Singh S, Troosters T, Ward S. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016;47:429-60. [DOI: 10.1183/13993003.00745-2015] [Cited by in Crossref: 208] [Cited by in F6Publishing: 181] [Article Influence: 34.7] [Reference Citation Analysis]
390 Ventetuolo CE, Kawut SM. What's the (end) point? Eur Respir J 2015;45:853-4. [PMID: 25726539 DOI: 10.1183/09031936.00191314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
391 Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006;36:49-53. [DOI: 10.1111/j.1365-2362.2006.01684.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
392 Raskin J, Qua D, Marks T, Sulica R. A retrospective study on the effects of pulmonary rehabilitation in patients with pulmonary hypertension. Chron Respir Dis 2014;11:153-62. [DOI: 10.1177/1479972314538980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
393 Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J, Barberá JA, Beghetti M, Corris P, Gaine S, Simon Gibbs J, Gómez-sánchez MÁ, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Española de Cardiología 2009;62:1464.e1-1464.e58. [DOI: 10.1016/s0300-8932(09)73130-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
394 Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Naslund JA, Wolfe R, Xie H, McHugo GJ, Jimenez DE, Jue K, Feldman J, Bird BL. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 2015;172:344-52. [PMID: 25827032 DOI: 10.1176/appi.ajp.2014.14030357] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 10.4] [Reference Citation Analysis]
395 Seyfarth H, Hammerschmidt S, Pankau H, Winkler J, Wirtz H. Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension. Respiration 2007;74:287-92. [DOI: 10.1159/000093322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
396 Karlsson A, Opava CH. Cycling or walking? Comparing the Six-minute walk with the cycle ergometer test in patients with rheumatoid arthritis. Advances in Physiotherapy 2009;10:203-8. [DOI: 10.1080/14038190802105870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
397 Weissmann N, Peters DM, Klöpping C, Krüger K, Pilat C, Katta S, Seimetz M, Ghofrani HA, Schermuly RT, Witzenrath M, Seeger W, Grimminger F, Mooren FC. Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. Am J Physiol Lung Cell Mol Physiol 2014;306:L986-95. [PMID: 24705723 DOI: 10.1152/ajplung.00275.2013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
398 Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009;39:495-501. [PMID: 19732197 DOI: 10.1111/j.1445-5994.2008.01880.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 177] [Article Influence: 15.5] [Reference Citation Analysis]
399 Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 2006;36:25-31. [DOI: 10.1111/j.1365-2362.2006.01685.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
400 Aschbrenner KA, Pratt SI, Bond GR, Zubkoff L, Naslund JA, Jue K, Williams G, Kinney A, Cohen MJ, Godfrey MM, Bartels SJ. A virtual learning collaborative to implement health promotion in routine mental health settings: Protocol for a cluster randomized trial. Contemporary Clinical Trials 2019;84:105816. [DOI: 10.1016/j.cct.2019.105816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
401 Karpman C, Benzo R. Gait speed as a measure of functional status in COPD patients. Int J Chron Obstruct Pulmon Dis 2014;9:1315-20. [PMID: 25473277 DOI: 10.2147/COPD.S54481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
402 Balashov K, Feldman DE, Savard S, Houde S, Frenette M, Ducharme A, Giannetti N, Michel C, Pilote L. Percent predicted value for the 6-minute walk test: using norm-referenced equations to characterize severity in persons with CHF. J Card Fail 2008;14:75-81. [PMID: 18226776 DOI: 10.1016/j.cardfail.2007.09.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
403 Pamidi S, Mehta S. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts? J Rheumatol. 2009;36:216-218. [PMID: 19208554 DOI: 10.3899/jrheum.081243] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
404 Ross RM, Murthy JN, Wollak ID, Jackson AS. The six minute walk test accurately estimates mean peak oxygen uptake. BMC Pulm Med. 2010;10:31. [PMID: 20504351 DOI: 10.1186/1471-2466-10-31] [Cited by in Crossref: 146] [Cited by in F6Publishing: 135] [Article Influence: 12.2] [Reference Citation Analysis]
405 Neal JE, Lee AS, Burger CD. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity: Exercise testing pulmonary arterial hypertension. The Clinical Respiratory Journal 2014;8:404-9. [DOI: 10.1111/crj.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
406 Khan AA, Tan J, Li W, Dimopoulos K, Spence MS, Chow P, Mullen MJ. The Impact of Transcatheter Atrial Septal Defect Closure in the Older Population. JACC: Cardiovascular Interventions 2010;3:276-81. [DOI: 10.1016/j.jcin.2009.12.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
407 Bourbonnais JM, Malaisamy S, Dalal BD, Samarakoon PC, Parikh SR, Samavati L. Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012;10:67. [PMID: 22694853 DOI: 10.1186/1477-7525-10-67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
408 Blanco I, Villaquirán C, Valera JL, Molina-molina M, Xaubet A, Rodríguez-roisin R, Barberà JA, Roca J. Consumo máximo de oxígeno durante la prueba de marcha de 6 minutos en la enfermedad pulmonar intersticial difusa y en la hipertensión pulmonar. Archivos de Bronconeumología 2010;46:122-8. [DOI: 10.1016/j.arbres.2009.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
409 Mclaughlin VV, Presberg KW, Doyle RL, Abman SH, Mccrory DC, Fortin T, Ahearn G. Prognosis of Pulmonary Arterial Hypertension*. Chest 2004;126:78S-92S. [DOI: 10.1378/chest.126.1_suppl.78s] [Cited by in Crossref: 371] [Cited by in F6Publishing: 89] [Article Influence: 20.6] [Reference Citation Analysis]
410 Sulica R, Poon M. Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine. Expert Review of Cardiovascular Therapy 2014;3:347-60. [DOI: 10.1586/14779072.3.2.347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
411 Natali D, Simonneau G, Humbert M, Montani D. [Investigation of pulmonary hypertension]. Rev Pneumol Clin 2008;64:151-61. [PMID: 18656791 DOI: 10.1016/j.pneumo.2008.05.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
412 Correa Rde A, Moreira MV, Saraiva JM, Mancuzo EV, Silva LC, Lambertucci JR. Treatment of schistosomiasis-associated pulmonary hypertension. J Bras Pneumol 2011;37:272-6. [PMID: 21537664 DOI: 10.1590/s1806-37132011000200018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
413 Zafrir N, Zingerman B, Solodky A, Ben-dayan D, Sagie A, Sulkes J, Mats I, Kramer MR. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. Int J Cardiovasc Imaging 2007;23:209-15. [DOI: 10.1007/s10554-006-9140-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
414 Vachiéry J, Pavelescu A. Exercise echocardiography in pulmonary hypertension. European Heart Journal Supplements 2007;9:H48-53. [DOI: 10.1093/eurheartj/sum022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
415 Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. British Journal of Haematology 2005;129:449-64. [DOI: 10.1111/j.1365-2141.2005.05432.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
416 Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. Six-Minute Walk Distance in Chronic Obstructive Pulmonary Disease: Reproducibility and Effect of Walking Course Layout and Length. Am J Respir Crit Care Med 2003;167:1522-7. [DOI: 10.1164/rccm.200203-166oc] [Cited by in Crossref: 220] [Cited by in F6Publishing: 75] [Article Influence: 11.6] [Reference Citation Analysis]
417 Johnson M, Thomson S. The Role of Exercise Testing in the Modern Management of Pulmonary Arterial Hypertension. Diseases 2014;2:120-47. [DOI: 10.3390/diseases2020120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
418 Wanderley FAC, Oliveira J, Mota J, Carvalho MJ. Six-minute walk distance (6MWD) is associated with body fat, systolic blood pressure, and rate-pressure product in community dwelling elderly subjects. Archives of Gerontology and Geriatrics 2011;52:206-10. [DOI: 10.1016/j.archger.2010.03.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
419 Valli G, Vizza CD, Onorati P, Badagliacca R, Ciuffa R, Poscia R, Brandimarte F, Fedele F, Serra P, Palange P. Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. Eur J Appl Physiol 2008;102:417-24. [PMID: 17978836 DOI: 10.1007/s00421-007-0600-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
420 Rafikov R, Rischard F, Vasilyev M, Varghese MV, Yuan JX, Desai AA, Garcia JG, Rafikova O. Cytokine Profiling in Pulmonary Arterial Hypertension: the Role of Redox Homeostasis and Sex. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.03.013] [Reference Citation Analysis]
421 Nolen-Doerr E, Crick K, Saha C, de Groot M, Pillay Y, Shubrook JH, Donley D, Hornsby WG Jr. Six-Minute Walk Test as a Predictive Measure of Exercise Capacity in Adults with Type 2 Diabetes. Cardiopulm Phys Ther J 2018;29:124-9. [PMID: 31379471 DOI: 10.1097/CPT.0000000000000080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
422 Idrees MM, Saleemi S, Azem MA, Aldammas S, Alhazmi M, Khan J, Gari A, Aldabbagh M, Sakkijha H, Aldalaan A, Alnajashi K, Alhabeeb W, Nizami I, Kouatli A, Chehab M, Tamimi O, Banjar H, Kashour T, Lopes A, Minai O, Hassoun P, Pasha Q, Mayer E, Butrous G, Bhagavathula S, Ghio S, Swiston J, Boueiz A, Tonelli A, Levy RD, Hoeper M, Levy RD. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Ann Thorac Med 2014;9:S1-S15. [PMID: 25076987 DOI: 10.4103/1817-1737.134006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
423 Bokhari S, Raina A, Berman Rosenweig E, Schulze PC, Bokhari J, Einstein AJ, Barst RJ, Johnson LL. PET Imaging May Provide a Novel Biomarker and Understanding of Right Ventricular Dysfunction in Patients With Idiopathic Pulmonary Arterial Hypertension. Circ Cardiovasc Imaging 2011;4:641-7. [DOI: 10.1161/circimaging.110.963207] [Cited by in Crossref: 74] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
424 Helman DL Jr, Brown AW, Jackson JL, Shorr AF. Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials. Chest 2007;132:764-72. [PMID: 17505027 DOI: 10.1378/chest.07-0236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
425 Zhong XJ, Jiang R, Yang L, Yuan P, Gong SG, Zhao QH, Luo CJ, Qiu HL, Li HT, Zhang R, He J, Wang L, Tang J, Liu JM. Peak oxygen uptake is a strong prognostic predictor for pulmonary hypertension due to left heart disease. BMC Cardiovasc Disord 2022;22:137. [PMID: 35361128 DOI: 10.1186/s12872-022-02574-0] [Reference Citation Analysis]
426 Van Albada ME, Loot FG, Fokkema R, Roofthooft MTR, Berger RMF. Biological Serum Markers in the Management of Pediatric Pulmonary Arterial Hypertension. Pediatr Res 2008;63:321-7. [DOI: 10.1203/pdr.0b013e318163a2e7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
427 Kawut SM, Palevsky HI. Surrogate end points for pulmonary arterial hypertension. American Heart Journal 2004;148:559-65. [DOI: 10.1016/j.ahj.2004.04.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
428 Nagel C, Prange F, Guth S, Herb J, Ehlken N, Fischer C, Reichenberger F, Rosenkranz S, Seyfarth HJ, Mayer E, Halank M, Grünig E. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012;7:e41603. [PMID: 22848542 DOI: 10.1371/journal.pone.0041603] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
429 Pielsticker EJ, Martinez FJ, Rubenfire M. Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001;20:1297-304. [PMID: 11744413 DOI: 10.1016/s1053-2498(01)00348-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
430 Ciurzyński M, Chrzanowska A, Bienias P, Domienik-Karłowicz J, Sobieraj P, Dąbrowska K, Dudzik-Niewiadomska I, Kurnicka K, Kisiel B, Pruszczyk P. Left ventricular diastolic dysfunction and diseases severity contribute to impaired exercise capacity in systemic lupus erythematosus. Lupus 2021;30:1154-62. [PMID: 33853418 DOI: 10.1177/09612033211006900] [Reference Citation Analysis]
431 Krishna BS, Mohapatra AK, Behera D, Jagaty SK, Subhankar S, Venkataram R, Dash DP. Six-Minute Walk Test and its Correlation with Spirometry in Stable COPD Patients. Journal of Health and Allied Sciences NU. [DOI: 10.1055/s-0041-1740331] [Reference Citation Analysis]
432 Soon E, Doughty NJ, Treacy CM, Ross RM, Toshner M, Upton PD, Sheares K, Morrell NW, Pepke-Zaba J. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. Pulm Circ 2011;1:244-9. [PMID: 22034610 DOI: 10.4103/2045-8932.83450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
433 Pang MY, Eng JJ, Dawson AS. Relationship between ambulatory capacity and cardiorespiratory fitness in chronic stroke: influence of stroke-specific impairments. Chest 2005;127:495-501. [PMID: 15705987 DOI: 10.1378/chest.127.2.495] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
434 Vieira EB, Ota-Arakaki JS, Dal Corso S, Ivanaga I, Fonseca AXC, Oliveira RKF, Rodrigues-Júnior JC, Ferreira EVM, Nery LE, Ramos RP. Incremental step test in patients with pulmonary hypertension. Respir Physiol Neurobiol 2020;271:103307. [PMID: 31557537 DOI: 10.1016/j.resp.2019.103307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
435 Güvenç TS, Kul Ş, Doğan C, Yıldırım BZ, Karabağ Y, Çetin R, Kaya Y, Karadağ P, Değirmencioğlu A, Balcı B. Assessment of right ventricular geometry and mechanics in chronic obstructive pulmonary disease patients living at high altitude. Int J Cardiovasc Imaging 2014;30:1305-13. [DOI: 10.1007/s10554-014-0475-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 Arif SA, Poon H. Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension. Clinical Therapeutics 2011;33:993-1004. [DOI: 10.1016/j.clinthera.2011.06.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
437 VanWagner LB, Uttal S, Lapin B, Lee J, Jichlinski A, Subramanian T, Heldman M, Poole B, Bustamante E, Gunasekaran S, Tapia CS, Veerappan A, Wong SY, Levitsky J. Use of Six-Minute Walk Test to Measure Functional Capacity After Liver Transplantation. Phys Ther 2016;96:1456-67. [PMID: 27055540 DOI: 10.2522/ptj.20150376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
438 Mclaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JSR, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 2009;54:S97-S107. [DOI: 10.1016/j.jacc.2009.04.007] [Cited by in Crossref: 152] [Cited by in F6Publishing: 134] [Article Influence: 11.7] [Reference Citation Analysis]
439 Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation 2010;29:181-7. [DOI: 10.1016/j.healun.2009.07.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
440 Browne AL, Appleton S, Fong K, Wood F, Coll F, de Munck S, Newnham E, Schug SA. A pilot randomized controlled trial of an early multidisciplinary model to prevent disability following traumatic injury. Disability and Rehabilitation 2012;35:1149-63. [DOI: 10.3109/09638288.2012.721047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
441 Casanova C, Cote C, Marin JM, Pinto-plata V, de Torres JP, Aguirre-jaíme A, Vassaux C, Celli BR. Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD. Chest 2008;134:746-52. [DOI: 10.1378/chest.08-0520] [Cited by in Crossref: 157] [Cited by in F6Publishing: 154] [Article Influence: 11.2] [Reference Citation Analysis]
442 Guo X, Lai J, Wang H, Tian Z, Wang Q, Zhao J, Li M, Fang Q, Fang L, Liu Y, Zeng X. Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging 2021;22:111-8. [PMID: 31872222 DOI: 10.1093/ehjci/jez311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
443 George MP, Champion HC, Pilewski JM. Lung transplantation for pulmonary hypertension. Pulm Circ 2011;1:182-91. [PMID: 22034605 DOI: 10.4103/2045-8932.83455] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
444 Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia 2015;70:56-70. [DOI: 10.1111/anae.12831] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
445 Steffen TM, Nelson RE. Measurement of Ambulatory Endurance in Adults. Topics in Geriatric Rehabilitation 2012;28:39-50. [DOI: 10.1097/tgr.0b013e318233e746] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
446 Shitrit D, Bendayan D, Bar-Gil-Shitrit A, Huerta M, Rudensky B, Fink G, Kramer MR. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002;122:1674-8. [PMID: 12426270 DOI: 10.1378/chest.122.5.1674] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
447 Ehlken N, Verduyn C, Tiede H, Staehler G, Karger G, Nechwatal R, Opitz CF, Klose H, Wilkens H, Rosenkranz S, Halank M, Grünig E. Economic Evaluation of Exercise Training in Patients with Pulmonary Hypertension. Lung 2014;192:359-66. [DOI: 10.1007/s00408-014-9558-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
448 Tanaka T, Morishita S, Hashimoto M, Itani Y, Mabuchi S, Kodama N, Hasegawa S, Domen K. Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma. Support Care Cancer 2017;25:2569-75. [DOI: 10.1007/s00520-017-3666-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
449 Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788. [PMID: 12204511 DOI: 10.1016/s0735-1097(02)02012-0] [Cited by in Crossref: 939] [Cited by in F6Publishing: 217] [Article Influence: 47.0] [Reference Citation Analysis]
450 Budweiser S, Heidtkamp F, Jörres RA, Heinemann F, Arzt M, Schroll S, Schmidbauer K, Hitzl AP, Pfeifer M. Predictive Significance of the Six-Minute Walk Distance for Long-Term Survival in Chronic Hypercapnic Respiratory Failure. Respiration 2008;75:418-26. [DOI: 10.1159/000109662] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
451 Harmsen WJ, Ribbers GM, Slaman J, Heijenbrok-Kal MH, Khajeh L, van Kooten F, Neggers SJ, van den Berg-Emons RJ. The six-minute walk test predicts cardiorespiratory fitness in individuals with aneurysmal subarachnoid hemorrhage. Top Stroke Rehabil 2017;24:250-5. [PMID: 27915583 DOI: 10.1080/10749357.2016.1260263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
452 Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young 2011;21:631-8. [DOI: 10.1017/s1047951111000497] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
453 Esposito JG, Thomas SG, Kingdon L, Ezzat S. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. Am J Physiol Endocrinol Metab 2005;289:E494-503. [PMID: 15886228 DOI: 10.1152/ajpendo.00013.2005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
454 Addetia K, Bhave NM, Tabit CE, Gomberg-Maitland M, Freed BH, Dill KE, Lang RM, Mor-Avi V, Patel AR. Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging 2014;7:115-24. [PMID: 24192452 DOI: 10.1161/CIRCIMAGING.113.000932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
455 Pascall E, Tulloh RM. Pulmonary hypertension in congenital heart disease. Future Cardiol 2018;14:343-53. [PMID: 29792339 DOI: 10.2217/fca-2017-0065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
456 Girotra S, Kitzman DW, Kop WJ, Stein PK, Gottdiener JS, Mukamal KJ. Heart rate response to a timed walk and cardiovascular outcomes in older adults: the cardiovascular health study. Cardiology 2012;122:69-75. [PMID: 22722364 DOI: 10.1159/000338736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
457 Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64:583-620. [PMID: 22659328 DOI: 10.1124/pr.111.005587] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
458 Chen YJ, Tu HP, Lee CL, Huang WC, Yang JS, Li CF, Chen CH, Lin KL. Comprehensive Exercise Capacity and Quality of Life Assessments Predict Mortality in Patients with Pulmonary Arterial Hypertension. Acta Cardiol Sin 2019;35:55-64. [PMID: 30713400 DOI: 10.6515/ACS.201901_35(1).20180608A] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
459 Papierniak ES, Lowenthal DT, Mubarak K. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. Am J Ther 2012;19:300-14. [PMID: 21642835 DOI: 10.1097/MJT.0b013e31820e828c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
460 Santana-Ribeiro AA, Moreira-Brasileiro GA, Aguiar-Oliveira MH, Salvatori R, Carvalho VO, Alvim-Pereira CK, Araújo-Daniel CR, Reis-Costa JG, Andrade-Guimarães AL, Oliveira-Santos AA, Vieira ER, Gois-Junior MB. Walking and postural balance in adults with severe short stature due to isolated GH deficiency. Endocr Connect 2019;8:416-24. [PMID: 30865930 DOI: 10.1530/EC-19-0103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
461 Puri S, Mehta V, Ahmed F, Banerjee A, Yusuf J, Mukhopadhyay S, Tyagi S. Correlation of early functional capacity with biventricular function and residual pulmonary artery hypertension following mitral valve replacement surgery. J Cardiopulm Rehabil Prev 2013;33:244-8. [PMID: 23748376 DOI: 10.1097/HCR.0b013e3182972db7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
462 Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006;48:1433-7. [PMID: 17010807 DOI: 10.1016/j.jacc.2006.05.070] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
463 Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;:CD004434. [PMID: 19588356 DOI: 10.1002/14651858.CD004434.pub4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
464 Paolillo S, Farina S, Bussotti M, Iorio A, Filardi PP, Piepoli MF, Agostoni P. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. Eur J Prev Cardiolog 2012;19:960-71. [DOI: 10.1177/1741826711426635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
465 Corte TJ, Mcdonagh TA, Wort SJ. Pulmonary hypertension in left heart disease: A review. International Journal of Cardiology 2012;156:253-8. [DOI: 10.1016/j.ijcard.2011.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
466 Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End points and clinical trial designs in pulmonary arterial hypertension. Journal of the American College of Cardiology 2004;43:S48-55. [DOI: 10.1016/j.jacc.2004.02.010] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 6.0] [Reference Citation Analysis]
467 Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JSR. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 2005;171:1292-7. [DOI: 10.1164/rccm.200410-1411oc] [Cited by in Crossref: 254] [Cited by in F6Publishing: 83] [Article Influence: 14.9] [Reference Citation Analysis]
468 Wauthy P, Pagnamenta A, Vassalli F, Naeije R, Brimioulle S. Right ventricular adaptation to pulmonary hypertension: an interspecies comparison. Am J Physiol Heart Circ Physiol 2004;286:H1441-7. [PMID: 14684368 DOI: 10.1152/ajpheart.00640.2003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 4.1] [Reference Citation Analysis]
469 Lavender M, Chia KS, Dwyer N, Corte TJ, Spencer L, Thakkar V, McWilliams T, Kotlyar E, Whitford H. Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. Expert Rev Respir Med 2018;12:965-77. [PMID: 30251562 DOI: 10.1080/17476348.2018.1527687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
470 Villalba WO, Sampaio-barros PD, Pereira MC, Cerqueira EM, Leme CA, Marques-neto JF, Paschoal IA. Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients. Chest 2007;131:217-22. [DOI: 10.1378/chest.06-0630] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
471 Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, Behr J. Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension. Am J Respir Crit Care Med 2004;170:360-5. [DOI: 10.1164/rccm.200308-1142oc] [Cited by in Crossref: 136] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
472 Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136:1202-10. [PMID: 19542256 DOI: 10.1378/chest.08-2988] [Cited by in Crossref: 162] [Cited by in F6Publishing: 141] [Article Influence: 12.5] [Reference Citation Analysis]
473 Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol 2009;147:737-43. [PMID: 19775299 DOI: 10.1111/j.1365-2141.2009.07906.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
474 Jiang R, Liu H, Pudasaini B, Zhang R, Xu JL, Wang L, Zhao QH, Yuan P, Guo J, He J, Gong SG, Wu C, Wu WH, Luo CJ, Qiu HL, Jing ZC, Liu JM. Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure. Clin Respir J 2019;13:148-58. [PMID: 30667180 DOI: 10.1111/crj.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
475 Leschke M, Wädlich A, Waldenmaier S, Faehling M. Diagnostik der pulmonalen Hypertonie. Internist 2009;50:1086-100. [DOI: 10.1007/s00108-009-2335-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
476 Saglam M, Arikan H, Vardar-yagli N, Calik-kutukcu E, Inal-ince D, Savci S, Akdogan A, Yokusoglu M, Kaya EB, Tokgozoglu L. Inspiratory Muscle Training in Pulmonary Arterial Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention 2015;35:198-206. [DOI: 10.1097/hcr.0000000000000117] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
477 Minai OA. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. Ann Thorac Med 2014;9:S92-7. [PMID: 25077003 DOI: 10.4103/1817-1737.134047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
478 Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ 2017;7:312-25. [PMID: 28597774 DOI: 10.1177/2045893217710639] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
479 Idrees M, Al-Najashi K, Khan A, Al-Dammas S, Al-Awwad H, Batubara E, Al Otai A, Abdulhameed J, Fayed A, Kashour T; SAPH Registry Taskforce. Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. Ann Thorac Med 2014;9:209-15. [PMID: 25276239 DOI: 10.4103/1817-1737.140127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
480 Morales-blanhir JE, Palafox Vidal CD, Rosas Romero MDJ, García Castro MM, Londoño Villegas A, Zamboni M. Teste de caminhada de seis minutos: uma ferramenta valiosa na avaliação do comprometimento pulmonar. J bras pneumol 2011;37:110-7. [DOI: 10.1590/s1806-37132011000100016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
481 Blanco I, Villaquirán C, Luis Valera J, Molina-molina M, Xaubet A, Rodríguez-roisin R, Barberà JA, Roca J. Peak Oxygen Uptake During the Six-minute Walk Test in Diffuse Interstitial Lung Disease and Pulmonary Hypertension. Archivos de Bronconeumología (English Edition) 2010;46:122-8. [DOI: 10.1016/s1579-2129(10)70032-x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
482 King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81. [PMID: 17901413 DOI: 10.1164/rccm.200705-732oc] [Cited by in Crossref: 347] [Cited by in F6Publishing: 122] [Article Influence: 23.1] [Reference Citation Analysis]
483 Mehari A, Klings ES. Chronic Pulmonary Complications of Sickle Cell Disease. Chest 2016;149:1313-24. [PMID: 26836905 DOI: 10.1016/j.chest.2015.11.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
484 Benza RL, Raina A, Gupta H, Murali S, Burden A, Zastrow MS, Park MH, Simon MA. Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. Pulm Circ 2018;8:2045893217741480. [PMID: 29064349 DOI: 10.1177/2045893217741480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
485 Strange G, Keogh AM, Williams TJ, Wlodarczyk J, Mcneil KD, Gabbay E. Bosentan therapy in patients with pulmonary arterial hypertension: The relationship between improvements in 6 minute walk distance and quality of life. Respirology 2008;13:674-82. [DOI: 10.1111/j.1440-1843.2008.01326.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
486 Zapico AG, Fuentes D, Rojo-Tirado MA, Calderón FJ, Rosenzweig EB, Garofano RP. Predicting Peak Oxygen Uptake From the 6-Minute Walk Test in Patients With Pulmonary Hypertension. J Cardiopulm Rehabil Prev 2016;36:203-8. [PMID: 26959496 DOI: 10.1097/HCR.0000000000000174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
487 Archer-chicko C. Nursing Care of Patients with Pulmonary Arterial Hypertension. In: Yuan JX-, Garcia JG, West JB, Hales CA, Rich S, Archer SL, editors. Textbook of Pulmonary Vascular Disease. Boston: Springer US; 2011. pp. 1531-58. [DOI: 10.1007/978-0-387-87429-6_111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
488 Saglam M, Vardar-Yagli N, Calik-Kutukcu E, Arikan H, Savci S, Inal-Ince D, Akdogan A, Tokgozoglu L. Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. J Phys Ther Sci 2015;27:1309-12. [PMID: 26157207 DOI: 10.1589/jpts.27.1309] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
489 Douwes JM, Hegeman AK, van der Krieke MB, Roofthooft MT, Hillege HL, Berger RM. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. International Journal of Cardiology 2016;202:34-9. [DOI: 10.1016/j.ijcard.2015.08.155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
490 Lind PA, Marks LB, Hollis D, Fan M, Zhou SM, Munley MT, Shafman TD, Jaszczak RJ, Coleman RE. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys 2002;54:340-7. [PMID: 12243806 DOI: 10.1016/s0360-3016(02)02932-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
491 Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan BA, Mantovani G, Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD; Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011;12:403-9. [PMID: 21640657 DOI: 10.1016/j.jamda.2011.04.014] [Cited by in Crossref: 617] [Cited by in F6Publishing: 533] [Article Influence: 56.1] [Reference Citation Analysis]
492 Torbicki A, Kurzyna M, Kuca P, Fijałkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzyńska L. Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension. Circulation 2003;108:844-8. [DOI: 10.1161/01.cir.0000084544.54513.e2] [Cited by in Crossref: 200] [Cited by in F6Publishing: 47] [Article Influence: 10.5] [Reference Citation Analysis]
493 Feldman DE, Ducharme A, Giannetti N, Frenette M, Michel C, Grondin F, Sheppard R, Lauriers JD, Behlouli H, Pilote L. Severity at entry to specialized heart failure clinics: discrepancies between health-related quality of life and function in men and women. Can J Cardiol 2011;27:382-7. [PMID: 21514784 DOI: 10.1016/j.cjca.2010.12.070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
494 Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, Mcgoon MD. Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry. Transplantation 2010;90:298-305. [DOI: 10.1097/tp.0b013e3181e49b83] [Cited by in Crossref: 55] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
495 Karpman C, DePew ZS, LeBrasseur NK, Novotny PJ, Benzo RP. Determinants of gait speed in COPD. Chest 2014;146:104-10. [PMID: 24522522 DOI: 10.1378/chest.13-2017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
496 Nead KT, Zhou M, Diaz Caceres R, Olin JW, Cooke JP, Leeper NJ. Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status. Circ Cardiovasc Qual Outcomes 2013;6:255-61. [PMID: 23633217 DOI: 10.1161/CIRCOUTCOMES.111.000070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
497 Zhang J, Wang Y, Zhang S, Li J, Fang H. Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients. Exp Ther Med 2020;19:2195-201. [PMID: 32104284 DOI: 10.3892/etm.2020.8431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
498 Fadel E, Mercier O, Mussot S, Fabre D, Humbert M, Simonneau G, Dartevelle P. [Surgical treatment of pulmonary arterial hypertension]. Rev Mal Respir 2011;28:139-51. [PMID: 21402229 DOI: 10.1016/j.rmr.2010.09.024] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
499 Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2006;:CD004434. [PMID: 16856046 DOI: 10.1002/14651858.CD004434.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
500 Nathan SD, Shlobin OA, Reese E, Ahmad S, Fregoso M, Athale C, Barnett SD. Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome. Respiratory Medicine 2009;103:1816-21. [DOI: 10.1016/j.rmed.2009.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
501 Hahn SS, Makaryus M, Talwar A, Narasimhan M, Zaidi G. A review of therapeutic agents for the management of pulmonary arterial hypertension. Ther Adv Respir Dis 2017;11:46-63. [PMID: 27595643 DOI: 10.1177/1753465816665289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
502 Montani D, Jaïs X, Sitbon O, Capron F, Simonneau G, Humbert M. Hypertension artérielle pulmonaire. Revue des Maladies Respiratoires 2005;22:651-66. [DOI: 10.1016/s0761-8425(05)85616-5] [Cited by in Crossref: 26] [Article Influence: 1.5] [Reference Citation Analysis]
503 Tiede H, Rorzyczka J, Dumitrascu R, Belly M, Reichenberger F, Ghofrani HA, Seeger W, Heitmann J, Schulz R. Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. BMC Pulm Med 2015;15:11. [PMID: 25888026 DOI: 10.1186/s12890-015-0005-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
504 Cunha-filho ITD, Henson H, Qureshy H, Williams AL, Holmes SA, Protas EJ. Differential responses to measures of gait performance among healthy and neurologically impaired individuals11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated. Archives of Physical Medicine and Rehabilitation 2003;84:1774-9. [DOI: 10.1016/s0003-9993(03)00373-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
505 Mainguy V, Malenfant S, Neyron AS, Saey D, Maltais F, Bonnet S, Provencher S. Alternatives to the six-minute walk test in pulmonary arterial hypertension. PLoS One 2014;9:e103626. [PMID: 25111294 DOI: 10.1371/journal.pone.0103626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
506 Corlateanu A, Plahotniuc A, Corlateanu O, Botnaru V, Bikov A, Mathioudakis AG, Covantev S, Siafakas N. Multidimensional indices in the assessment of chronic obstructive pulmonary disease. Respir Med 2021;185:106519. [PMID: 34175803 DOI: 10.1016/j.rmed.2021.106519] [Reference Citation Analysis]
507 Antonelli-Incalzi R, Corsonello A, Pedone C, Trojano L, Acanfora D, Spada A, Izzo O, Rengo F. Drawing impairment predicts mortality in severe COPD. Chest 2006;130:1687-94. [PMID: 17166983 DOI: 10.1378/chest.130.6.1687] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
508 Saouti N, de Man F, Westerhof N, Boonstra A, Twisk J, Postmus PE, Noordegraaf AV. Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respiratory Medicine 2009;103:1013-9. [DOI: 10.1016/j.rmed.2009.01.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
509 Montani D, Yaïci A, Jaïs X, Sztrymf B, Cabrol S, Hamid A, Parent F, Sitbon O, Dartevelle P, Simonneau G, Humbert M. Hypertension artérielle pulmonaire. EMC - Pneumologie 2006;3:1-27. [DOI: 10.1016/s1155-195x(06)43390-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
510 Mackenzie AM, Peacock AJ. Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose? Curr Hypertens Rep 2015;17. [DOI: 10.1007/s11906-015-0560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
511 Caminati A, Bianchi A, Cassandro R, Rosa Mirenda M, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respiratory Medicine 2009;103:117-23. [DOI: 10.1016/j.rmed.2008.07.022] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 5.5] [Reference Citation Analysis]
512 Duffels M, van Loon L, Berger R, Boonstra A, Vonk-noordergraaf A, Mulder B. Pulmonary Arterial Hypertension Associated with a Congenital Heart Defect: Advanced Medium-term Medical Treatment Stabilizes Clinical Condition. Congenital Heart Disease 2007;2:242-9. [DOI: 10.1111/j.1747-0803.2007.00104.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
513 Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ 2011;1:138-59. [PMID: 22034603 DOI: 10.4103/2045-8932.83444] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
514 Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res 2014;115:115-30. [PMID: 24951762 DOI: 10.1161/CIRCRESAHA.115.301146] [Cited by in Crossref: 201] [Cited by in F6Publishing: 110] [Article Influence: 25.1] [Reference Citation Analysis]
515 Hauck A, Guo R, Ivy DD, Younoszai A. Tricuspid annular plane systolic excursion is preserved in young patients with pulmonary hypertension except when associated with repaired congenital heart disease. Eur Heart J Cardiovasc Imaging 2017;18:459-66. [PMID: 27099276 DOI: 10.1093/ehjci/jew068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
516 Athanasiou KA, Sahni S, Rana A, Talwar A. Diagnosing and managing scleroderma-related pulmonary arterial hypertension. JAAPA 2017;30:11-8. [PMID: 28858011 DOI: 10.1097/01.JAA.0000522129.93995.13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
517 Camillo CA, Langer D, Osadnik CR, Pancini L, Demeyer H, Burtin C, Gosselink R, Decramer M, Janssens W, Troosters T. Survival after pulmonary rehabilitation in patients with COPD: impact of functional exercise capacity and its changes. Int J Chron Obstruct Pulmon Dis 2016;11:2671-9. [PMID: 27822029 DOI: 10.2147/COPD.S113450] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
518 Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, Douglas DD. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16:1373-1378. [PMID: 21117246 DOI: 10.1002/lt.22167] [Cited by in Crossref: 168] [Cited by in F6Publishing: 154] [Article Influence: 15.3] [Reference Citation Analysis]
519 Hsieh MH, Fang YF, Chung FT, Lee CS, Chang YC, Liu YZ, Wu CH, Lin HC. Distance-saturation product of the 6-minute walk test predicts mortality of patients with non-cystic fibrosis bronchiectasis. J Thorac Dis 2017;9:3168-76. [PMID: 29221293 DOI: 10.21037/jtd.2017.08.53] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
520 Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 2003;41:1380-6. [DOI: 10.1016/s0735-1097(03)00121-9] [Cited by in Crossref: 243] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
521 Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One 2018;13:e0193226. [PMID: 29590122 DOI: 10.1371/journal.pone.0193226] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
522 Tobin M. Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000. Am J Respir Crit Care Med 2001;164:1789-804. [DOI: 10.1164/ajrccm.164.10.2108126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
523 Idrees M, Alnajashi K, Abdulhameed J, Khan A, Batubara E, Alotay A, Fayed A, Aldammas S, Alseif M, Alawwad H, Abusabaa Y, Almobrad M, Kashour T; Registry Taskforce SAPH. Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin. Ann Thorac Med 2015;10:204-11. [PMID: 26229564 DOI: 10.4103/1817-1737.160842] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
524 Alhamad EH, Shaik SA, Idrees MM, Alanezi MO, Isnani AC. Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010;10:42. [PMID: 20696064 DOI: 10.1186/1471-2466-10-42] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
525 Zou L, SasaKi JE, Wang H, Xiao Z, Fang Q, Zhang M. A Systematic Review and Meta-Analysis Baduanjin Qigong for Health Benefits: Randomized Controlled Trials. Evid Based Complement Alternat Med 2017;2017:4548706. [PMID: 28367223 DOI: 10.1155/2017/4548706] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 14.4] [Reference Citation Analysis]
526 Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respiratory Medicine 2010;104:1588-607. [DOI: 10.1016/j.rmed.2010.08.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
527 Radchenko GD, Zhyvylo IO, Sirenko YM. Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first Ukrainian register). Pulm Circ 2019;9:2045894019845604. [PMID: 30942126 DOI: 10.1177/2045894019845604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
528 Ferraz AP, Seara FAC, Baptista EF, Barenco TS, Sottani TBB, Souza NSC, Domingos AE, Barbosa RAQ, Takiya CM, Couto MT, Resende GO, Campos de Carvalho AC, Ponte CG, Nascimento JHM. BKCa Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats. Cardiovasc Drugs Ther 2021;35:719-32. [PMID: 33245463 DOI: 10.1007/s10557-020-07115-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
529 Frantz RP, McGoon MD. Diagnostic dilemmas in pulmonary hypertension. Heart Fail Clin 2012;8:331-52. [PMID: 22748898 DOI: 10.1016/j.hfc.2012.04.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
530 Salvi D, Poffley E, Tarassenko L, Orchard E. App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study. JMIR Mhealth Uhealth 2021;9:e22748. [PMID: 34096876 DOI: 10.2196/22748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Grünig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, Gorenflo M, Holt S, Kovacs G, Ley S, Meyer JF, Pabst S, Riemekasten G, Saur J, Schwaiblmair M, Seck C, Sinn L, Sorichter S, Winkler J, Leuchte HH. Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. International Journal of Cardiology 2011;154:S3-S12. [DOI: 10.1016/s0167-5273(11)70488-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
532 Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2021;3:CD004434. [PMID: 33765691 DOI: 10.1002/14651858.CD004434.pub6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Elinoff JM, Rame JE, Forfia PR, Hall MK, Sun J, Gharib AM, Abd-Elmoniem K, Graninger G, Harper B, Danner RL, Solomon MA. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. Trials 2013;14:91. [PMID: 23547564 DOI: 10.1186/1745-6215-14-91] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
534 Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55-S66. [PMID: 19555859 DOI: 10.1016/j.jacc.2009.04.011] [Cited by in Crossref: 752] [Cited by in F6Publishing: 615] [Article Influence: 57.8] [Reference Citation Analysis]
535 American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211-277. [PMID: 12524257 DOI: 10.1164/rccm.167.2.211] [Cited by in Crossref: 1755] [Cited by in F6Publishing: 1581] [Article Influence: 92.4] [Reference Citation Analysis]
536 Taichman DB, Mandel J. Epidemiology of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 2013;34:619-37. [DOI: 10.1016/j.ccm.2013.08.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
537 Golpe R, Castro-Añón O, Pérez-de-Llano LA, González-Juanatey C, Muñiz-Fernández C, Testa-Fernández A, Pérez-Fernández R. Prognostic significance of six-minute walk test in non-group 1 pulmonary hypertension. Heart Lung 2014;43:72-6. [PMID: 24041565 DOI: 10.1016/j.hrtlng.2013.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
538 Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant 2015;34:338-47. [PMID: 25703961 DOI: 10.1016/j.healun.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
539 Jaijee S, O'rourke R, Puranik R, Slaughter R, Strugnal W, Celermajer D, Kermeen F. RETRACTED: Right to left ventricular volume ratio: A novel marker of disease severity in chronic thromboembolic pulmonary hypertension. IJC Heart & Vessels 2013;1:17-21. [DOI: 10.1016/j.ijchv.2013.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
540 Yılmaz BC, Güçlü MB, Keleş MN, Taçoy GA, Çengel A. Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension. Heart Lung 2020;49:564-71. [PMID: 32457004 DOI: 10.1016/j.hrtlng.2020.04.006] [Reference Citation Analysis]
541 Toro R, Cabeza-Letrán ML, Quezada M, Rodriguez-Puras MJ, Mangas A. Impaired right and left ventricular mechanics in adults with pulmonary hypertension and congenital shunts. J Cardiovasc Med (Hagerstown) 2016;17:209-16. [PMID: 25079043 DOI: 10.2459/JCM.0000000000000172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
542 Malenfant S, Lebret M, Breton-Gagnon É, Potus F, Paulin R, Bonnet S, Provencher S. Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. Eur Respir Rev 2021;30:200284. [PMID: 33853885 DOI: 10.1183/16000617.0284-2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
543 Pekmezi D, Ainsworth C, Joseph R, Bray MS, Kvale E, Isaac S, Desmond R, Meneses K, Marcus B, Demark-Wahnefried W. Rationale, design, and baseline findings from HIPP: A randomized controlled trial testing a home-based, individually-tailored physical activity print intervention for African American women in the Deep South. Contemp Clin Trials 2016;47:340-8. [PMID: 26944022 DOI: 10.1016/j.cct.2016.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
544 Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ. Updating clinical endpoint definitions. Pulm Circ 2013;3:206-16. [PMID: 23662199 DOI: 10.4103/2045-8932.109920] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
545 Pereira JLF, Galant LH, Rosa LHTD, Garcia E, BrandÃo ABM, Marroni CA. CAPACITY OF EXERCISE AND SURVIVAL IN PATIENTS WITH CIRRHOSIS WITH AND WITHOUT HEPATOPULMONARY SYNDROME AFTER LIVER TRANSPLANTATION. Arq Gastroenterol 2020;57:262-6. [PMID: 32935745 DOI: 10.1590/S0004-2803.202000000-49] [Reference Citation Analysis]
546 Kohl Lde M, Signori LU, Ribeiro RA, Silva AM, Moreira PR, Dipp T, Sbruzzi G, Lukrafka JL, Plentz RD. Prognostic value of the six-minute walk test in end-stage renal disease life expectancy: a prospective cohort study. Clinics (Sao Paulo) 2012;67:581-6. [PMID: 22760895 DOI: 10.6061/clinics/2012(06)06] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
547 Galiè N, Manes A, Branzi A. Evaluation of pulmonary arterial hypertension: . Current Opinion in Cardiology 2004;19:575-81. [DOI: 10.1097/01.hco.0000142066.14966.85] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
548 Roberts MM, Cho J, Sandoz JS, Wheatley JR. Oxygen desaturation and adverse events during 6-min walk testing in patients with COPD: Desaturation and adverse events in 6MWT. Respirology 2015;20:419-25. [DOI: 10.1111/resp.12471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
549 Rausch CM, Taylor AL, Ross H, Sillau S, Ivy DD. Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. Int J Cardiol 2013;169:445-8. [PMID: 24144928 DOI: 10.1016/j.ijcard.2013.10.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
550 Guimarães GV, Carvalho VO, Bocchi EA. Reproducibility of the self-controlled six-minute walking test in heart failure patients. Clinics (Sao Paulo) 2008;63:201-6. [PMID: 18438574 DOI: 10.1590/s1807-59322008000200008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
551 Mao J, Zhang J, Zhou S, Das S, Hollis DR, Folz RJ, Wong TZ, Marks LB. Updated assessment of the six-minute walk test as predictor of acute radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 2007;67:759-67. [PMID: 17293233 DOI: 10.1016/j.ijrobp.2006.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
552 Keeratichananont W, Thanadetsuntorn C, Keeratichananont S. Value of preoperative 6-minute walk test for predicting postoperative pulmonary complications. Ther Adv Respir Dis 2016;10:18-25. [PMID: 26546478 DOI: 10.1177/1753465815615509] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
553 Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009;36:330-336. [PMID: 19208563 DOI: 10.3899/jrheum.080447] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 6.7] [Reference Citation Analysis]
554 Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702-710. [PMID: 21335128 DOI: 10.1016/j.jtcvs.2010.11.024] [Cited by in Crossref: 380] [Cited by in F6Publishing: 304] [Article Influence: 34.5] [Reference Citation Analysis]
555 Fraidenburg DR, Machado RF. Pulmonary hypertension associated with thalassemia syndromes. Ann N Y Acad Sci. 2016;1368:127-139. [PMID: 27008311 DOI: 10.1111/nyas.13037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
556 Barberà JA. Clinical research in pulmonary hypertension comes of age. Arch Bronconeumol 2014;50:463-4. [PMID: 24998025 DOI: 10.1016/j.arbres.2014.05.001] [Reference Citation Analysis]
557 Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, Mccormack MC, Macintyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1447-78. [DOI: 10.1183/09031936.00150414] [Cited by in Crossref: 343] [Cited by in F6Publishing: 313] [Article Influence: 42.9] [Reference Citation Analysis]
558 Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med 2006;38:95-110. [PMID: 16581695 DOI: 10.1080/07853890600622143] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
559 Brown AJ, Davison E, Sleeper MM. Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. J Vet Intern Med 2010;24:850-4. [PMID: 20412435 DOI: 10.1111/j.1939-1676.2010.0517.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
560 Kowal-bielecka O, Delcroix M, Vonk-noordegraaf A, Hoeper MM, Naeije R. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis. Rheumatology 2008;47:v39-41. [DOI: 10.1093/rheumatology/ken308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
561 Farina S, Correale M, Bruno N, Paolillo S, Salvioni E, Badagliacca R, Agostoni P; “Right and Left Heart Failure Study Group” of the Italian Society of Cardiology. The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. Eur Respir Rev 2018;27:170134. [PMID: 29720508 DOI: 10.1183/16000617.0134-2017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
562 Quarck R, Nawrot T, Meyns B, Delcroix M. C-Reactive Protein. Journal of the American College of Cardiology 2009;53:1211-8. [DOI: 10.1016/j.jacc.2008.12.038] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 11.3] [Reference Citation Analysis]
563 Silva MDS, Martins AC, Cipriano G, Ramos LR, Lopes GS. Inspiratory training increases insulin sensitivity in elderly patients: Insulin sensitivity and aging. Geriatrics & Gerontology International 2012;12:345-51. [DOI: 10.1111/j.1447-0594.2011.00755.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
564 DePew ZS, Karpman C, Novotny PJ, Benzo RP. Correlations between gait speed, 6-minute walk distance, physical activity, and self-efficacy in patients with severe chronic lung disease. Respir Care 2013;58:2113-9. [PMID: 23696689 DOI: 10.4187/respcare.02471] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
565 Mathai SC. Solvitur ambulando…or maybe not? Chest 2013;143:285-7. [PMID: 23381304 DOI: 10.1378/chest.12-1819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
566 Alameri H, Al-majed S, Al-howaikan A. Six-min walk test in a healthy adult Arab population. Respiratory Medicine 2009;103:1041-6. [DOI: 10.1016/j.rmed.2009.01.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
567 Ciurzyński M, Bienias P, Irzyk K, Kostrubiec M, Bartoszewicz Z, Siwicka M, Stelmaszczyk-Emmel A, Górska E, Demkow U, Pruszczyk P. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol 2014;33:83-9. [PMID: 23942766 DOI: 10.1007/s10067-013-2354-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
568 Tsukada J, Yamada Y, Kawakami T, Matsumoto S, Inoue M, Nakatsuka S, Okada M, Fukuda K, Jinzaki M. Treatment effect prediction using CT after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Radiol 2021;31:5524-32. [PMID: 33569619 DOI: 10.1007/s00330-021-07711-5] [Reference Citation Analysis]
569 Ibrahim R, Granton JT, Mehta S. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. Can Respir J 2006;13:415-20. [PMID: 17149459 DOI: 10.1155/2006/746176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
570 Sinclair R, Batterham A, Davies S, Cawthorn L, Danjoux G. Validity of the 6 min walk test in prediction of the anaerobic threshold before major non-cardiac surgery. British Journal of Anaesthesia 2012;108:30-5. [DOI: 10.1093/bja/aer322] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
571 Zafrir B. Exercise Training and Rehabilitation in Pulmonary Arterial Hypertension: RATIONALE AND CURRENT DATA EVALUATION. Journal of Cardiopulmonary Rehabilitation and Prevention 2013;33:263-73. [DOI: 10.1097/hcr.0b013e3182a0299a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
572 Troost E, Delcroix M, Gewillig M, Van Deyk K, Budts W. A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension. Catheter Cardiovasc Interv 2009;73:173-9. [PMID: 19085938 DOI: 10.1002/ccd.21760] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
573 Gadre A, Ghattas C, Han X, Wang X, Minai O, Highland KB. Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study. Lung 2017;195:529-36. [PMID: 28646245 DOI: 10.1007/s00408-017-0034-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
574 Sarkar MS, Desai PM. Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective. Ann Card Anaesth 2018;21:116-22. [PMID: 29652270 DOI: 10.4103/aca.ACA_123_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
575 Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. Am Heart J 2011;162:562-8. [PMID: 21884877 DOI: 10.1016/j.ahj.2011.06.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
576 Sanges S, Giovannelli J, Sobanski V, Morell-Dubois S, Maillard H, Lambert M, Podevin C, Lamblin N, De Groote P, Bervar JF, Perez T, Matran R, Rémy-Jardin M, Hatron PY, Hachulla É, Launay D. Factors associated with the 6-minute walk distance in patients with systemic sclerosis. Arthritis Res Ther 2017;19:279. [PMID: 29246248 DOI: 10.1186/s13075-017-1489-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
577 Schwaiblmair M, Faul C, von Scheidt W, Berghaus TM. Detection of exercise-induced pulmonary arterial hypertension by cardiopulmonary exercise testing. Clin Cardiol 2012;35:548-53. [PMID: 22588968 DOI: 10.1002/clc.22009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
578 Martinu T, Babyak MA, O’Connell CF, Carney RM, Trulock EP, Davis RD, Blumenthal JA, Palmer SM. Baseline 6-min walk distance predicts survival in lung transplant candidates. Am J Transplant. 2008;8:1498-1505. [PMID: 18510641 DOI: 10.1111/j.1600-6143.2008.02264.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
579 Sanges S, Launay D, Rhee RL, Sitbon O, Hachulla É, Mouthon L, Guillevin L, Rottat L, Montani D, De Groote P, Cottin V, Magro P, Prévot G, Bauer F, Bergot E, Chabanne C, Reynaud-Gaubert M, Leroy S, Canuet M, Sanchez O, Gut-Gobert C, Dauphin C, Pison C, Boissin C, Habib G, Clerson P, Conesa F, Cordier JF, Kawut SM, Simonneau G, Humbert M. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2016;75:1457-65. [PMID: 26324844 DOI: 10.1136/annrheumdis-2015-207336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
580 Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94. [PMID: 20507945 DOI: 10.1378/chest.10-0260] [Cited by in Crossref: 254] [Cited by in F6Publishing: 204] [Article Influence: 21.2] [Reference Citation Analysis]
581 Weatherald J, Farina S, Bruno N, Laveneziana P. Cardiopulmonary Exercise Testing in Pulmonary Hypertension. Annals ATS 2017;14:S84-92. [DOI: 10.1513/annalsats.201610-788fr] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
582 Stevens GR, Lala A, Sanz J, Garcia MJ, Fuster V, Pinney S. Exercise Performance in Patients With Pulmonary Hypertension Linked to Cardiac Magnetic Resonance Measures. The Journal of Heart and Lung Transplantation 2009;28:899-905. [DOI: 10.1016/j.healun.2009.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
583 Raza F, Dharmavaram N, Hess T, Dhingra R, Runo J, Chybowski A, Kozitza C, Batra S, Horn EM, Chesler N, Eldridge M. Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest VE /VCO2 and ETCO2 identify pulmonary vascular disease. Clin Cardiol 2022. [PMID: 35419844 DOI: 10.1002/clc.23831] [Reference Citation Analysis]
584 Dambrauskaite V, Delcroix M, Claus P, Herbots L, D’hooge J, Bijnens B, Rademakers F, Sutherland GR. Regional right ventricular dysfunction in chronic pulmonary hypertension. J Am Soc Echocardiogr. 2007;20:1172-1180. [PMID: 17570637 DOI: 10.1016/j.echo.2007.02.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 6.2] [Reference Citation Analysis]
585 Troy LK, Young IH, Lau EM, Corte TJ. Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia: Exercise and oxygen in IIP. Respirology 2016;21:1005-14. [DOI: 10.1111/resp.12650] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
586 Mathai SC, Hassoun PM. Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med. 2011;5:267-279. [PMID: 21510736 DOI: 10.1586/ers.11.18] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
587 Alhamad EH. The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med 2009;4:60-4. [PMID: 19561926 DOI: 10.4103/1817-1737.49414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
588 Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IM, Roux S, Rubin LJ, Simonneau G, Sitbon O, Tapson VF. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research 2002;63:227-46. [DOI: 10.1016/s0011-393x(02)80029-7] [Cited by in Crossref: 22] [Article Influence: 1.1] [Reference Citation Analysis]
589 Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745-755. [PMID: 16818116 DOI: 10.1016/j.healun.2006.03.011] [Cited by in Crossref: 745] [Cited by in F6Publishing: 596] [Article Influence: 46.6] [Reference Citation Analysis]
590 Ryan JJ, Marsboom G, Archer SL. Rodent Models of Group 1 Pulmonary Hypertension. In: Humbert M, Evgenov OV, Stasch J, editors. Pharmacotherapy of Pulmonary Hypertension. Berlin: Springer Berlin Heidelberg; 2013. pp. 105-49. [DOI: 10.1007/978-3-662-45805-1_5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
591 Lapier TK. Utility of the late life function and disability instrument as an outcome measure in patients participating in outpatient cardiac rehabilitation: a preliminary study. Physiother Can 2012;64:53-62. [PMID: 23277685 DOI: 10.3138/ptc.2010-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
592 Mendes AA, Roncal CGP, Oliveira FRA, Albuquerque ES, Góes GHB, Piscoya ICV, Sobral Filho DC. Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. Rev Soc Bras Med Trop 2020;53:e20190418. [PMID: 32049203 DOI: 10.1590/0037-8682-0418-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
593 Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006;7:1487-501. [PMID: 16859432 DOI: 10.1517/14656566.7.11.1487] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
594 Goldstein SA, Krasuski RA. Pulmonary Hypertension in Adults with Congenital Heart Disease. Cardiol Clin 2022;40:55-67. [PMID: 34809917 DOI: 10.1016/j.ccl.2021.08.006] [Reference Citation Analysis]
595 Otero González I, Blanco Aparicio M, Souto Alonso A, Raposo Sonnenfeld I, Verea Hernando H. Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III. Archivos de Bronconeumología 2007;43:272-6. [DOI: 10.1157/13101954] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]